WO2001083517A1 - Stat4 and stat6 binding dipeptide derivatives - Google Patents
Stat4 and stat6 binding dipeptide derivatives Download PDFInfo
- Publication number
- WO2001083517A1 WO2001083517A1 PCT/US2000/012079 US0012079W WO0183517A1 WO 2001083517 A1 WO2001083517 A1 WO 2001083517A1 US 0012079 W US0012079 W US 0012079W WO 0183517 A1 WO0183517 A1 WO 0183517A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- aryl
- compound
- member selected
- Prior art date
Links
- 230000027455 binding Effects 0.000 title description 11
- 108010016626 Dipeptides Proteins 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 147
- 239000000203 mixture Substances 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 31
- 125000003118 aryl group Chemical group 0.000 claims description 129
- 125000000217 alkyl group Chemical group 0.000 claims description 112
- -1 4-carbamoylphenyl Chemical group 0.000 claims description 77
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 67
- 229910052739 hydrogen Inorganic materials 0.000 claims description 66
- 239000001257 hydrogen Substances 0.000 claims description 57
- 150000001413 amino acids Chemical group 0.000 claims description 43
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 229940024606 amino acid Drugs 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 28
- 125000005842 heteroatom Chemical group 0.000 claims description 26
- 108010011005 STAT6 Transcription Factor Proteins 0.000 claims description 25
- 102000013968 STAT6 Transcription Factor Human genes 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 125000005647 linker group Chemical group 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 23
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 23
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 claims description 20
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 17
- 229960004452 methionine Drugs 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 13
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 13
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 13
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 13
- 229960002429 proline Drugs 0.000 claims description 13
- 206010020751 Hypersensitivity Diseases 0.000 claims description 11
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 11
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 229960003136 leucine Drugs 0.000 claims description 11
- 229960004295 valine Drugs 0.000 claims description 11
- 150000007649 L alpha amino acids Chemical group 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 9
- 239000004395 L-leucine Substances 0.000 claims description 9
- 235000019454 L-leucine Nutrition 0.000 claims description 9
- 229960003767 alanine Drugs 0.000 claims description 9
- 229960000310 isoleucine Drugs 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 150000007650 D alpha amino acids Chemical group 0.000 claims description 8
- 229930182844 L-isoleucine Natural products 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 6
- 229930195722 L-methionine Natural products 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 6
- 229960002898 threonine Drugs 0.000 claims description 6
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 5
- 206010001889 Alveolitis Diseases 0.000 claims description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 5
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 5
- 206010010741 Conjunctivitis Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 206010012442 Dermatitis contact Diseases 0.000 claims description 5
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 5
- 208000024780 Urticaria Diseases 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 201000010105 allergic rhinitis Diseases 0.000 claims description 5
- 230000007815 allergy Effects 0.000 claims description 5
- 230000036783 anaphylactic response Effects 0.000 claims description 5
- 208000003455 anaphylaxis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 208000010247 contact dermatitis Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 5
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 230000005951 type IV hypersensitivity Effects 0.000 claims description 5
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 5
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 229960001153 serine Drugs 0.000 claims description 4
- 229960004441 tyrosine Drugs 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 3
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 2
- 108010061435 Enalapril Proteins 0.000 claims description 2
- RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical compound Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 claims description 2
- 108010007859 Lisinopril Proteins 0.000 claims description 2
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N Seratrodast Chemical compound O=C1C(C)=C(C)C(=O)C(C(CCCCCC(O)=O)C=2C=CC=CC=2)=C1C ZBVKEHDGYSLCCC-UHFFFAOYSA-N 0.000 claims description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004335 azelastine hydrochloride Drugs 0.000 claims description 2
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 claims description 2
- 229960002882 calcipotriol Drugs 0.000 claims description 2
- 229960001803 cetirizine Drugs 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 229960001338 colchicine Drugs 0.000 claims description 2
- 229960000265 cromoglicic acid Drugs 0.000 claims description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 229960000860 dapsone Drugs 0.000 claims description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 2
- 229960000873 enalapril Drugs 0.000 claims description 2
- 229960003449 epinastine Drugs 0.000 claims description 2
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 claims description 2
- 229960000354 fexofenadine hydrochloride Drugs 0.000 claims description 2
- 229960000289 fluticasone propionate Drugs 0.000 claims description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 2
- 229960002848 formoterol Drugs 0.000 claims description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 2
- 229940015045 gold sodium thiomalate Drugs 0.000 claims description 2
- 229960001361 ipratropium bromide Drugs 0.000 claims description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 2
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 claims description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 2
- 229960002394 lisinopril Drugs 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 claims description 2
- 229960001951 montelukast sodium Drugs 0.000 claims description 2
- 229960002052 salbutamol Drugs 0.000 claims description 2
- 229960005018 salmeterol xinafoate Drugs 0.000 claims description 2
- 229960003090 seratrodast Drugs 0.000 claims description 2
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 claims description 2
- 229960002051 trandolapril Drugs 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 229960004764 zafirlukast Drugs 0.000 claims description 2
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims description 2
- 229960002769 zofenopril Drugs 0.000 claims description 2
- 229930182821 L-proline Natural products 0.000 claims 10
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 6
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 6
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 150000001555 benzenes Chemical group 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 abstract description 2
- 229940121354 immunomodulator Drugs 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 45
- 238000002360 preparation method Methods 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 30
- 238000000746 purification Methods 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 125000001424 substituent group Chemical group 0.000 description 24
- 239000007787 solid Substances 0.000 description 22
- 150000003839 salts Chemical class 0.000 description 18
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 13
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000002378 acidificating effect Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 0 CCN(C*1C)NC1C(C)=O Chemical compound CCN(C*1C)NC1C(C)=O 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 229930182817 methionine Natural products 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000000132 electrospray ionisation Methods 0.000 description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000010933 acylation Effects 0.000 description 6
- 238000005917 acylation reaction Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- FMUMEWVNYMUECA-LURJTMIESA-N (2s)-2-azaniumyl-5-methylhexanoate Chemical compound CC(C)CC[C@H](N)C(O)=O FMUMEWVNYMUECA-LURJTMIESA-N 0.000 description 4
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 4
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 4
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 4
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- 229910018828 PO3H2 Inorganic materials 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 3
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 3
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 2
- LWHHAVWYGIBIEU-LURJTMIESA-N (2s)-2-methylpyrrolidin-1-ium-2-carboxylate Chemical compound [O-]C(=O)[C@]1(C)CCC[NH2+]1 LWHHAVWYGIBIEU-LURJTMIESA-N 0.000 description 2
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 2
- UYZNMRJCNSDDFV-BKLSDQPFSA-N (2s)-4-chloropyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(Cl)CN1 UYZNMRJCNSDDFV-BKLSDQPFSA-N 0.000 description 2
- SMWADGDVGCZIGK-AXDSSHIGSA-N (2s)-5-phenylpyrrolidine-2-carboxylic acid Chemical compound N1[C@H](C(=O)O)CCC1C1=CC=CC=C1 SMWADGDVGCZIGK-AXDSSHIGSA-N 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- AAFXQFIGKBLKMC-KQQUZDAGSA-N (e)-3-[4-[(e)-2-carboxyethenyl]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(\C=C\C(O)=O)C=C1 AAFXQFIGKBLKMC-KQQUZDAGSA-N 0.000 description 2
- TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- RDBBJCUJCNMAAF-UHFFFAOYSA-N 2-azaniumyl-3-methoxy-3-methylbutanoate Chemical compound COC(C)(C)C(N)C(O)=O RDBBJCUJCNMAAF-UHFFFAOYSA-N 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 2
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 2
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000000887 Transcription factor STAT Human genes 0.000 description 2
- 108050007918 Transcription factor STAT Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000003975 aryl alkyl amines Chemical class 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- YCBJOQUNPLTBGG-UHFFFAOYSA-N ethyl 4-iodobenzoate Chemical compound CCOC(=O)C1=CC=C(I)C=C1 YCBJOQUNPLTBGG-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940043230 sarcosine Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- ZHXAZZQXWJJBHA-UHFFFAOYSA-N triphenylbismuthane Chemical compound C1=CC=CC=C1[Bi](C=1C=CC=CC=1)C1=CC=CC=C1 ZHXAZZQXWJJBHA-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- FUOSTELFLYZQCW-UHFFFAOYSA-N 1,2-oxazol-3-one Chemical compound OC=1C=CON=1 FUOSTELFLYZQCW-UHFFFAOYSA-N 0.000 description 1
- PAHVTLRWCQYFEB-UHFFFAOYSA-N 1,2-oxazolidine-3,5-dione Chemical compound O=C1CC(=O)ON1 PAHVTLRWCQYFEB-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- RZYHXKLKJRGJGP-UHFFFAOYSA-N 2,2,2-trifluoro-n,n-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)N([Si](C)(C)C)C(=O)C(F)(F)F RZYHXKLKJRGJGP-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- BHZBRPQOYFDTAB-UHFFFAOYSA-N 2-(4-bromophenyl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CC=C(Br)C=C1 BHZBRPQOYFDTAB-UHFFFAOYSA-N 0.000 description 1
- QVHJQCGUWFKTSE-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical group OC(=O)C(C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- LRFZIPCTFBPFLX-UHFFFAOYSA-N 3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)C(C)(C)C LRFZIPCTFBPFLX-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VLVCDUSVTXIWGW-UHFFFAOYSA-N 4-iodoaniline Chemical compound NC1=CC=C(I)C=C1 VLVCDUSVTXIWGW-UHFFFAOYSA-N 0.000 description 1
- NJAKCIUOTIPYED-UHFFFAOYSA-N 4-iodobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(I)C=C1 NJAKCIUOTIPYED-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- SLWRTVINHWIGTK-UHFFFAOYSA-N 5-methylsulfonylthiophene-2-carboxylic acid Chemical compound CS(=O)(=O)C1=CC=C(C(O)=O)S1 SLWRTVINHWIGTK-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- QCEPAZSRRGCQJL-VMPITWQZSA-N CCOC(c1ccc(/C=C/C(O)=O)cc1)=O Chemical compound CCOC(c1ccc(/C=C/C(O)=O)cc1)=O QCEPAZSRRGCQJL-VMPITWQZSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102000007078 STAT Transcription Factors Human genes 0.000 description 1
- 108010072819 STAT Transcription Factors Proteins 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000005165 aryl thioxy group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- PELJISAVHGXLAL-UHFFFAOYSA-N iodomethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCI PELJISAVHGXLAL-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 125000004492 methyl ester group Chemical group 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates generally to dipeptide compounds and, more particularly, to novel dipeptide analogs and compositions, their preparation and their use as modulators of the immune system.
- STATs Signal Transducers and Activators of Transcription
- STATs are activated by contact with the phosphorylated cytokine receptor; activation results in the STAT polypeptides forming a dimer and entering the nucleus, where the STAT dimer binds to the regulatory region of a gene that is inducible by the particular cytokine. Binding of the activated STAT dimer triggers transcription of the gene.
- the STAT polypeptides (STAT1, STAT2, STAT4, STAT5a, STAT5b, and STAT6) have molecular masses from 84-113 kDa.
- Each STAT protein contains a Src homology-2 (SH2) domain capable of recognizing one or more phosphotyrosine sequences in the cytoplasmic portion of the activated receptor (Shuai et al. (1993) Nature 366: 580).
- SH2 Src homology-2
- each cytokine receptor is specific for a particular STAT protein, and each STAT activates transcription of certain genes, thereby providing two layers of specificity in cytokine-induced signalling.
- STAT6 and STAT4 are two proteins that are intimately involved in regulation of immune responses.
- STAT4 transduces to the nucleus signals from the IL-12 receptor.
- IL-12 is involved in the development of a T H 1 immune response (Kaplan et al. (1996) Nature 382: 174-177), which is part of an organism's defense against intracellular pathogens.
- IL-12 is also necessary for the T-cell-independent induction of the cytokine interferon (IFN)- ⁇ , which is a key step in the initial suppression of bacterial and parasitic infections.
- IFN cytokine interferon
- Knockout mice which lack STAT4 were found to be defective in all IL-12 functions tested, including the induction of IFN-gamma, mitogenesis, enhancement of natural killer cytolytic function and T H 1 differentiation (Thierfelder et al. (1996) Nature 382: 171-174).
- IL-4 signals are transduced to the nucleus by STAT6.
- IL-4 is a key cytokine in the initiation of a T H 2 immune response, and also activates B and T lymphocytes.
- STAT6-deficient mice were shown to be deficient in IL-4 activities (Kaplan et al. (1996) Immunity 4: 313-319; Takeda et al. (1996) Nature 380: 627-630; Shimoda et al. (1996) Nature 380: 630-633).
- STAT4 and STAT6 are important in modulating the immune response of an organism, both in response to infection and in undesirable conditions such as inflammation, allergic reactions, and autoimmune diseases.
- Intervention at the STAT level would have significant advantages compared to previous approaches, which typically target the IL-4 or IL-12 cytokine itself, or the interaction of the cytokine with the receptor. Disruption of cytokine function itself can cause a variety of undesirable side effects. These can be avoided by intervening at the level of STAT-mediated signal transduction.
- identification of agents that can modulate STAT4 and STAT6-mediated signal transduction has heretofore been hampered by the lack of suitable assays.
- the present invention provides compounds which are represented by the formula:
- R 1 and R 2 are each independently selected from hydrogen, (C r C 8 )alkyl, (C r C 8 )heteroalkyl, aryl, aryl(C 1 -C 8 )alkyl, aryl(C C 8 )heteroalkyl, heteroaryl, heteroaryl(C,-C 3 )alkyl, and heteroaryl(C 1 -C 8 )heteroalkyl, with the proviso that at least one of R 1 and R 2 is selected from aryl, aryl(C I -C 8 )alkyl, aryl(C 1 -C 8 )heteroalkyl, heteroaryl, heteroaryl(C 1 -C 8 )alkyl and heteroary ⁇ C ) - C 8 )heteroalkyl.
- a 1 represents a divalent L- ⁇ -amino acid or D- ⁇ -amino acid fragment or a fragment having the formula:
- R 3 is hydrogen or (C r C 4 ) alkyl
- R 4 and R 5 are each independently selected from hydrogen, (C r C 8 )alkyl, (C r C 8 )heteroalkyl, aryl, aryl(C r C 8 )alkyl or aryl(C r C 8 )heteroalkyl, or R 4 and R 5 can be individually combined with R 3 to form a 5- , 6-, 7- or 8-membered ring containing from one to three heteroatoms.
- a 2 represents an L- ⁇ -amino acid or D- ⁇ -amino acid fragment or a fragment having the formula:
- R 6 is either hydrogen or (C r C 4 )alkyl;
- R 7 and R s are independently selected from hydrogen, (C r C 8 )alkyl, (C r C 8 )heteroalkyl, aryl, aryl(C r C 8 )alkyl or aryl(C,-C 8 )heteroalkyl, or R 7 and R 8 can be combined with each other to form a 5-, 6-, 7- or 8-membered ring containing from zero to three heteroatoms.
- the wavy line is meant to indicate the point of attachment to the remainder of the molecule.
- the amino acid fragments are those portions of an amino acid that remain after removal of the OH group from the carboxylic acid portion and a hydrogen atom from the ⁇ -amino portion.
- the letter X represents a bond, a (C ⁇ ) saturated or unsaturated alkyl linking group or a (C r C 4 ) saturated or unsaturated heteroalkyl linking group.
- Y represents an acidic moiety, an isostere of an acidic moiety or an ester of an acidic moiety that can be converted to an acidic moiety in vivo.
- the acidic moiety (or ester or isostere) is attached to Ar either directly or with a spacer. Accordingly, Y can be represented as a group of formula:
- Z 1 represents a member selected from -CO 2 R 9 , -P(O)(OR 9 )(OR 10 ), -P(O)(R 9 )(OR 10 ), -S(O) 2 (OR 9 ), -S(O)(OR 9 ) and a carboxylic acid isostere.
- the symbol Z 2 represents a member selected from -CO 2 R 9 , -NHR 11 , -P(O)(OR 9 )(OR 10 ), -P(O)(R 9 )(OR 10 ), -S(O) 2 (OR 9 ), -S(O)(OR 9 ) and a carboxylic acid isostere.
- R 9 and R 10 each independently represent H, (C r C 8 )alkyl or (C r C 8 )heteroalkyl; and R 11 represents (C r C 8 )alkyl.
- Ar represents an aryl or heteroaryl group.
- the compounds of the present invention are useful in compositions that further comprise a pharmaceutically acceptable excipient. Both the compounds and compositions of the present inventions are useful for the diagnosis and treatment (including prophylactic treatment) of conditions mediated through STAT signaling.
- conditions associated with STAT signaling include, but are not limited to: Thl -mediated conditions such as delayed-type hypersensitivity, contact dermatitis, uveitis, Crohn's disease, psoriasis and autoimmune diseases (typically associated with STAT4 signaling); Th2-mediated diseases such as allergic rhinitis, asthma, scleroderma, eczema and conjunctivitis (typically associated with STAT6 signaling); proliferative disorders such as cancers (associated with STAT3 and/or STAT5 signaling); and STAT1 conditions which are similar to those described for STAT4, but typically observed in more acute situations such as acute transplant rejections.
- a variety of additional conditions associated with STAT signaling include atopic dermatitis, anaphylaxis, food or drug induced allergy, hypersensitivity reactions, alveolitis, Churg-Strauss syndrome, urticaria, angiodema, and systemic lupus erythematosus.
- Figure 1 provides the structures for certain particularly preferred compounds of the present invention.
- Figure 2 illustrates the solid-phase synthesis of compounds of the present invention.
- Figure 3 provides structures for certain dicarboxylic acids that are useful in preparing compounds of formula I.
- alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i. e. Cj-Cio means one to ten carbons).
- saturated hydrocarbon radicals include groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)ethyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
- An unsaturated alkyl group is one having one or more double bonds or triple bonds.
- alkyl groups examples include vinyl, 2-propenyl, crotyl, 2-iso ⁇ entenyl, 2- (butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3- butynyl, and the higher homologs and isomers.
- alkylene by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified by -CH 2 CH 2 CH 2 CH 2 -.
- an alkyl or alkylene group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention.
- a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
- alkoxy refers to those groups having an alkyl group attached to the remainder of the molecule through an oxygen, nitrogen or sulfur atom, respectively.
- dialkylamino is used in a conventional sense to refer to -NR'R" wherein the R groups can be the same or different alkyl groups.
- heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
- the heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group.
- the heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule.
- heteroalkyl Up to two heteroatoms may be consecutive, such as, for example, -CH 2 -NH-OCH 3 and -CH 2 -O-Si(CH 3 ) 3 .
- heteroalkyl also included in the term “heteroalkyl” are those radicals described in more detail below as “heterocycloalkyl.”
- heteroalkylene by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified by -CH 2 -CH 2 -S-CH 2 CH 2 - and -CH 2 - S-CH 2 -CH 2 -NH-CH 2 -.
- heteroatoms can also occupy either or both of the chain termini. Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied.
- acyl refers to those groups derived from an organic acid by removal of the hydroxy portion of the acid. Accordingly, acyl is meant to include, for example, acetyl, propionyl, butyryl, decanoyl, pivaloyl, benzoyl and the like.
- cycloalkyl and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
- heterocycloalkyl examples include 1 -(1,2,5,6-tetrahydropyridyl), 1 -piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3- yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
- halo or halogen
- substituents mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
- fluoroalkyl are meant to include monofluoroalkyl and polyfluoroalkyl.
- aryl employed alone or in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) means, unless otherwise stated, an aromatic substituent which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently.
- heteroaryl is meant to include those aryl rings which contain from zero to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
- the “heteroaryl” groups can be attached to the remainder of the molecule through a heteroatom.
- Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1 -pyrrolyl, 2- pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4- oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2- thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3- pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2- benzimidazolyl, 5-indoly
- arylalkyl is meant to include those radicals in which an aryl or heteroaryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) or a heteroalkyl group (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(l- naphthyloxy)propyl, and the like).
- R', R" and R'" each independently refer to hydrogen, unsubstituted(C r C 8 )alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl-(C 1 -C 4 )alkyl groups.
- R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
- -NR'R is meant to include 1-pyrrolidinyl and 4-morpholinyl.
- alkyl is meant to include groups such as haloalkyl (e.g., -CF 3 and -CH 2 CF 3 ) and acyl (e.g., -C(O)CH 3 , -C(O)CF 3 , - C(O)CH 2 OCH 3 , and the like).
- Two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CH 2 ) q -U-, wherein T and U are independently -NH-, -O-, -CH 2 - or a single bond, and the subscript q is an integer of from 0 to 2.
- two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) r -B-, wherein A and B are independently -CH 2 - 3 -O-, -NH-, -S-, -S(O , -S(O) 2 -, -S(O) 2 NR'- or a single bond, and r is an integer of from 1 to 3.
- One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
- two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula -(CH 2 ) s -X-(CH 2 ) t -, where s and t are independently integers of from 0 to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O) 2 -, or -S(O) 2 NR'-.
- the substituent R' in -NR'- and -S(O) 2 NR' ⁇ is selected from hydrogen or unsubstituted (C r C 6 )alkyl.
- heteroatom is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).
- salts are meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
- pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, oxalic, maleic, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
- inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phospho
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S.M., et al, "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1911, 66, 1-19).
- Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
- the present invention provides compounds which are in a prodrug form.
- Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention.
- prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
- Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.
- the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
- the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
- the compounds of the present invention can be conjugated to easily-detectable groups, such as fluorescein or biotin, for use as reagents or diagnostic tools. Additionally, such tagged compounds can be further attached to a solid support (e.g., bead, resin or microtiter plate)and used in binding experiments to discover other compounds that interact with STAT6.
- easily-detectable groups such as fluorescein or biotin
- the present invention provides compounds, compositions and methods for the inhibition or treatment of conditions or disorders modulated by the STAT transcription factors, particularly STAT4 and STAT6. Additionally, the compounds are useful for the diagnosis of conditions dependent on STAT signaling. Without intending to be bound by a theory, it is believed that certain compounds of the present invention block interaction between phosphorylated tyrosine residues in the IL-4 receptor and the SH2 domain of STAT6. In this manner, phosphorylation (i.e., activation) of STAT6 by IL-4-receptor-associated kinases is prevented.
- the compounds exert their effect by interfering with the dimerization of STAT6 monomers that is required before the STAT6 dimer can bind to the STAT6-dependent genes and initiate transcription of, for example, germline epsilon transcript.
- the compounds, compositions and methods of the present invention will be useful in treating (suppressing or inhibiting) the full spectrum of immune disorders which require transcriptional activation by STAT6 dimer, including allergic conditions (e.g., allergic rhinitis, asthma, atopic dermatitis, contact dermatitis, anaphylaxis, food or drug induced allergy, conjunctivitis, uveitis, hypersensitivity reactions, alveolitis and psoriasis), Churg-Strauss syndrome, delayed- type hypersensitivity, urticaria, angiodema, eczema, scleroderma, and systemic lupus erythematosus.
- allergic conditions e.g., allergic rhinitis, asthma, atopic dermatitis, contact dermatitis, anaphylaxis, food or drug induced allergy, conjunctivitis, uveitis, hypersensitivity reactions, alveolitis and psoriasis
- the present invention provides compounds which are represented by the the formula:
- R 1 and R 2 are each independently selected from hydrogen, (C r C 8 )alkyl, (C r C 8 )heteroalkyl, aryl, aryl(C 1 -C 8 )alkyl, aryl(C r C 8 )heteroalkyl, heteroaryl, heteroaryl(C r C 8 )alkyl and heteroary ⁇ C j -C ⁇ heteroalkyl, with the proviso that at least one of R 1 and R 2 is selected from aryl, aryl(C ⁇ -C 8 )alkyl, aryl(C 1 -C 8 )heteroalkyl, heteroaryl, heteroaryl(C 1 -C 8 )alkyl and heteroaryl(C r C 8 )heteroalkyl.
- R 1 is selected from (C r C 8 )alkyl and (C r C 8 )heteroalkyl
- R 2 is selected from aryl, aryl(C ⁇ -C 8 )alkyl, and ary ⁇ C,- C 8 )heteroalkyl. More preferably, R 2 is selected from aryl and aryl(C,-C 8 )alkyl. Still more preferably, R 1 is selected from (C r C 4 )alkyl and R 2 is substituted or unsubstituted aryl. Most preferred are those embodiments in which R 2 is an optionally substituted phenyl or optionally substituted benzyl group.
- R 1 and R 2 are each selected from aryl, aryl(C r C 8 )alkyl and aryl(C 1 -C 8 )heteroalkyl.
- R 1 and R 2 are each independently an optionally substituted phenyl group.
- R 1 and R 2 are both optionally substituted benzyl groups.
- R 1 is an optionally substituted phenyl group and R 2 is an optionally substituted benzyl group.
- the substituents on the aryl rings can be any of those substituents described above in the definitions section.
- R 1 and R 2 are phenyl or benzyl groups and the additional substituents occupy positions on the benzene ring that are meta or para to the positions at which the benzene rings are attached to the remainder of the molecule.
- the symbol A 1 represents a divalent L- ⁇ -amino acid or D- ⁇ -amino acid fragment or a fragment having the formula:
- R 3 is hydrogen or ( -Q alkyl
- R 4 and R 5 are each independently selected from hydrogen, ( -C ⁇ alkyl, ( -C ⁇ heteroalkyl, aryl, aryl(C r C 8 )alkyl or or R 4 and R 5 can be individually combined with R 3 to form a 5- , 6-, 7- or 8-membered ring containing from one to three heteroatoms.
- a 1 is described as an amino acid or an amino acid fragment, what is meant is a residue of the amino acid that typically remains upon incorporation of the amino acid into a peptide or other similar linear array or polymer.
- a 1 is " alanine,” the term is meant to refer to that fragment that is typically incorporated into a peptide or protein (i.e., -NH-CH(CH 3 )-C(O)-).
- a 1 is an amino acid selected from 2-aminoisobutyric acid, sarcosine, norvaline, homoserine, citrulline, norleucine, 2,3-diaminopropionic acid, methionine oxide, methionine dioxide, penicillamine, homoleucine, ornithine, 3H- dehydroproline, 2-methylproline, homoproline, 5-phenylproline, 4-chloroproline, proline, tyrosine, serine, methionine and alanine.
- a 1 is a fragment having the formula above in which R 5 is hydrogen and R 3 and R 4 are combined to form a 5-, 6-, or 7-membered ring containing from one to three heteroatoms. More preferably, R 3 and R 4 are combined to form a 5-membered ring containing from one to three heteroatoms. In other preferred embodiments, A 1 is a fragment selected from
- E 1 , E 2 , E 3 and E 4 each independently represent C, N, S or O, with the proviso that the 5-, 6- or 7-membered ring contains no more than three heteroatoms as ring members.
- E 1 to E 4 are C or N, the remaining valences can be occupied by bonds to hydrogen, aryl, (C r C 8 )heteroalkyl, aryl(C r C 8 )alkyl, aryl(C 1 -C 8 )heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl.
- the remaining valence is occupied by (C r C 8 )alkyl, most preferably substituted (C,-C 8 )alkyl (e.g., acetyl, propionyl and the like).
- a 1 is represented by the formula:
- W 1 represents H, -OR 12 or -NR 12 R 13 .
- the R 12 and R 13 groups independently represent hydrogen, aryl, (C 1 -C 8 )alkyl, ( -C ⁇ heteroalkyl, aryl(C,-C 8 )alkyl, aryl(C,- C 8 )heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl.
- W 1 is - NHCOCH 3 , -NHCOCH 2 CH 2 NHAc, -NH 2 , -NH-tosyl, -NHCOPh, -NHCOCH(CH 3 ) 2 , -NHSO 2 CH 3 , -NHCO 2 CH 2 Ph, -N(CH 3 ) 2 , and -N(CH 2 Ph) 2 .
- the W 1 group can have either a cis or trans orientation relative to the carbonyl group at the 2-position of the pyrrolidine ring, or can exist as a mixture of isomers at the center bearing the W 1 group.
- a 2 represents an L- ⁇ -amino acid or D- ⁇ -amino acid fragment or a fragment having the formula:
- R 6 is either hydrogen or (C r C 4 )alkyl;
- R 7 and R 8 are independently selected from hydrogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )heteroalkyl, aryl, aryl(C,-
- a 2 represents an amino acid selected from norvaline, homoserine, cyclohexylalanine, norleucine, diaminopropionic acid, methionine oxide, homoleucine, ornithine, tert-butylglycine, 3 -methoxy valine, allothreonine, valine, tlireonine, leucine, isoleucine, lysine and methionine.
- a 2 is selected from L- valine, L-leucine, L-lysine, L-methionine. L-threonine, L-isoleucine and L- tert-butylglycine. Most preferably, A 2 is L-valine or L-tert-butylglycine. As with the definition of A 1 , one of skill in the art will understand that when A 2 is described as an amino acid or an amino acid fragment, what is meant is a residue of the amino acid that typically remains upon incorporation of the amino acid into a peptide or other similar linear array or polymer.
- X represents a bond, a (C r C 4 ) saturated or unsaturated alkyl linking group or a (C,-C 4 ) saturated or unsaturated heteroalkyl linking group.
- Ar represents an aryl or heteroaryl group.
- aryl and heteroaryl groups are useful in the present invention.
- Preferred aryl and heteroaryl groups include benzene, naphthalene, pyridine, furan, imidazole, pyrazole, thiophene. biphenyl, dihydronaphthalene, 1,2,3-triazole and pyrazine.
- Particularly preferred is benzene in which the X and Y groups are attached to the benzene ring at positions para to each other.
- Ar is benzene, X and Y are attached at positions para to each other, and the benzene ring is further substituted with at least one additional substituent selected from -halogen, -OR', - OC(O)R ⁇ -NR'R", -SR', -R', -CN, -NO 2 , -CO 2 R', -CONR'R", -OC(O)NR'R", - NR"C(O)R', -NR"C(O) 2 R', perfluoro(C r C 4 )alkoxy, and perfluoro(C 1 -C 4 )alkyl, where R' and R" are independently selected from hydrogen, (C r C 8 )alkyl, (C,-C 8 )heteroalkyl, and unsubstituted aryl.
- Y represents an acidic moiety, an isostere of an acidic moiety or an ester of an acidic moiety that can be converted to an acidic moiety in vivo.
- the acidic moiety (or ester or isostere) is attached to Ar either directly or with a spacer. Accordingly, Y can be represented as a group of formula:
- divalent linking group and “trivalent linking group” are meant to include groups having two and three available valences respectively, for covalent attachment to Ar, Z 1 and Z 2 .
- the linking groups typically serve as scaffolds to preserve a certain orientation or spacing between Z 1 or Z 2 and Ar.
- the linking groups will typically comprise from one to eight carbon atoms.
- from one to three of the carbon atoms will be replaced with a heteroatom (e.g., O, N S, Si).
- B 1 can be a longer homolog of the above linking groups, for example a three-carbon or four-carbon alkylene group which is optionally substituted with additional alkyl groups, halogen atoms or heteroatoms.
- Trivalent (B 2 ) linking groups that are useful in the present invention include, for example,
- the symbol Z 1 represents a member selected from -CO 2 R 9 , -P(O)(OR 9 )(OR 10 ), -P(O)(R 9 )(OR 10 ), -S(O) 2 (OR 9 ), -S(O)(OR 9 ) and a carboxylic acid isostere.
- the symbol Z 2 represents a member selected from -CO 2 R 9 , -NHR 11 , -P(O)(OR 9 )(OR 10 ), -P(O)(R 9 )(OR 10 ), -S(O) 2 (OR 9 ), -S(O)(OR 9 ) and a carboxylic acid isostere.
- R 9 and R 10 each independently represent H, (C r C 8 )alkyl, aryl or and R 11 represents (C,-C 8 )alkyl, preferably a substituted (C,-C 8 )alkyl group (e.g., acetyl, propionyl, butanoyl, and the like).
- Z 1 and Z 2 are selected from -CO 2 H, -PO 3 H 2 , -P(O)(CH 3 )(OH) and a carboxylic acid isostere.
- carboxylic acid isosteres are known to those of skill in the art, including, for example, tetrazole, amidotetrazole, methanesulfonamide, 3-isoxazolone, isoxazolidine-3,5- dione and 1,2,4-triazole (see, e.g., Ornstein, et al, J. Med. Chem. 39:2232-2244 (1996) and Lipinski, Ann. Reports Med. Chem. 21:283-291 (1986).
- Z 1 and Z 2 are selected from -CO 2 H and -PO 3 H 2 .
- 7) and Z 2 are selected from -CO 2 R 9 , -P(O)(OR 9 )(OR 10 ) and -P(O)(R 9 )(OR 10 ), in which R 9 and R 10 are each independently selected from (C r C 8 )alkyl and (C r C 8 )heteroalkyl.
- Suitable alkyl and heteroalkyl groups include, for example, methyl, ethyl, propyl, isopropyl, tert-butyl, sec-butyl, isobutyl, methoxymethyl, methoxyethyl, acetoxymethyl, propionyloxymethyl and pivaloyloxymethyl (-CH 2 OC(O)C(CH 3 ) 3 ).
- W 1 represents hydrogen, -OR 12 or -NR 12 R 13 ;
- the symbols W 2 , W 3 and W 4 each independently represent hydrogen, halogen, -R 14 , -CO 2 R 14 , -OR 14 , -NR 14 R 15 or -CONR 14 R 15 ;
- each of R 12 , R 13 , R 14 and R 15 independently represent hydrogen, aryl, (C r C 8 )alkyl, ( -C ⁇ heteroalkyl, aryl(C r C 8 )alkyl, aryl(C,- C 8 )heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl;
- the symbol W 5 represents a hydrogen or (C,-C 8 )alkyl.
- R 7 and Y can be any of the groups defined for general formula (I), above.
- R 7 is selected from ethyl, isopropyl, isobutyl, tert-butyl, sec-butyl, cyclohexylmethyl, and 2-methoxy-2-propyl.
- the compound has the formula:
- the symbol W 1 represents hydrogen, -OR 12 or -NR 12 R 13 ; the symbols W 2 and W 3 each independently represent hydrogen, halogen, -R 14 , -CO 2 R 14 , -OR 14 , -NR 14 R 15 or -CONR 14 R 15 ; wherein each of R 12 , R 13 , R 14 and R 15 independently represent hydrogen, aryl, (C r C 8 )alkyl, (C 1 -C 8 )heteroalkyl, aryl(C r C 8 )alkyl, aryl(C r C 8 )heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl; the symbol W 5 represents a hydrogen or (C 1 -C 8 )alkyl; and the symbol W 6 represents a
- the remaining symbols, R 7 and Y can be any of the groups defined for general formula (I), above. Preferred groups for the symbols noted and those defined
- the symbol W 1 represents hydrogen, -OR 12 or -NR 12 R 13 ; the symbols W 2 , W 3 and W 4 each independently represent hydrogen, halogen, -R 14 , -CO 2 R 14 , -OR 14 , -NR 14 R 15 or -CONR 14 R 15 ; wherein each of R 12 , R 13 , R 14 and R 15 independently represent hydrogen, aryl, (C 1 -C 8 )alkyl, (C r C 8 )heteroalkyl, aryl(C C 8 )heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl; and the symbol W 5 represents a hydrogen or (C,-C 8 )alkyl.
- the remaining symbols, R 7 and Y can be any of the groups defined for general formula (I), above. Preferred groups for the symbols noted and those defined above are the same as the preferred groups provided for formula Ila.
- the compounds of the present invention are useful in therapeutic as well as prophylactic and diagnostic applications, and are also useful in drug discovery research. Accordingly, the present invention provides suitably modified derivatives of the above compound in such a manner that their interaction with a STAT6 molecule (or fragment thereof) can be easily detected by physical or chemical means.
- the present invention further provides compositions containing the above compounds and pharmaceutically acceptable excipients or diagnostically acceptable excipients. Still further, the invention provides methods of treating conditions or diseases, particularly those mediated by STAT6 signaling.
- Such conditions or diseases include allergic conditions (e.g., allergic rhinitis, asthma, atopic dermatitis, contact dermatitis, anaphylaxis, food or drug induced allergy, conjunctivitis, uveitis, hypersensitivity reactions, alveolitis and psoriasis), Churg-Strauss syndrome, delayed-type hypersensitivity, urticaria, angiodema, eczema, scleroderma, and systemic lupus erythematosus.
- the present invention also provides methods for prophylactic treatments to prevent the onset of the above- noted disorders in patients.
- the invention provides methods of treating conditions such as those above, by administering to a subject in need of such treatment a therapeutic regimen comprising a compound provided herein, in combination with another agent such as, for example, loratidine, fluticasone propionate, beclametasone diproprionate, budesonide, salmeterol xinafoate, ipratropium bromide, fexofenadine hydrochloride, cetirizine dihydrochloride, triamcinolone acetonide, cromolyn, salbutamol, montelukast sodium, ketotifen hydrogen fumarate, formoterol, zafirlukast, momefasone furoate, azelastine hydrochloride, epinastine, seratrodast, captropril, rampril, zofenopril, colchicine, enalapril, lisinopril, trando
- another agent such
- the amount of each agent administered may be less than the amount required when the agent is used alone.
- the agents are synergistic with the compounds provided herein and can be used in amount that are less than one-half of the normal efficacious dose.
- the administration of the agents can be simultaneous or sequential. In instances wherein administration is sequential, the agents can be administered in any order and the periods between administration of a first and second agent can be minutes, hours, days, weeks, or months.
- Scheme 1 provides a general outline for the synthesis of compounds in which A 1 is an L- ⁇ -amino acid (alanine), A 2 is an L- ⁇ -amino acid (valine), and R 1 and R 2 are both aryl groups.
- compounds of the present invention can be prepared by substituting Boc-alanine (i) with suitably protected forms of any of the following non-limiting examples: 2-aminoisobutyric acid, sarcosine, norvaline, homoserine, citrulline, norleucine, 2,3 -diaminopropionic acid, methionine oxide, methionine dioxide, penicillamine, homoleucine, ornithine, 3H-dehydroproline, 2- methylproline, homoproline, 5-phenylproline, 4-chloroproline, proline, tyrosine, serine, and methionine.
- Boc-valine can be substituted with suitably protected forms of, for example, norvaline, homoserine, cyclohexylalanine, norleucine, diaminopropionic acid, methionine oxide, homoleucine, omithine, tert- butylglycine, 3 -methoxy valine, allothreonine, threonine, leucine, isoleucine, lysine and methionine.
- the acid vi can be replaced in the synthesis scheme with a variety of other acids (see, for example, the acids depicted in Scheme 4 and those prepared in Example 3.3).
- Scheme 2 illustrates a synthesis outline for the preparation of compounds in which R 1 is a substituted phenyl and R 2 is benzyl (or a substituted benzyl).
- synthesis begins as outlined in Scheme 1 to provide iii.
- Conversion of iii to amide viii can be accomplished by treating iii with sodium hydride and benzyl bromide. The remaining steps are essentially the same as those steps described in Scheme 1.
- removal of the Boc group in viii, followed by attachment of Boc-leucine and conversion of the methyl ester to an amide (with ammonia) results in formation of ix.
- Conversion of ix to x follows those steps which were outlined for the conversion of v to vii.
- Scheme 3 provides a synthesis outline for compound in which R 1 and R 2 are each benzyl.
- R 1 and R 2 are each benzyl.
- One of skill in the art will understand that the method provided will be applicable to other arylalkylamines and substituted arylalkylamines.
- condensation of benzaldehyde and benzylamine, and reduction of the Schiff base initially produced yields dibenzylamine xii.
- Acylation of xii with Boc-proline provides xiii, which can be deprotected and acylated with Boc-t- butylglycine to provide xiv.
- Deprotection of xiv and acylation with 1,4- phenylenediacrylic acid provides the target compound xv.
- Substitution patterns on the benzene ring portions of R 1 and R 2 can be varied by starting the synthesis outlined in Scheme 3 with alternative substituted benzaldehydes and substituted benzylamines. Coupling the resultant dibenzylamine derivative with various amino acids (or alternatively, a dipeptide) and acylation of the N-terminous provides compound of the present invention.
- Scheme 4 provides reaction schemes for preparing carboxylic acids that effectively add Y-Ar-X-C(O)- to the dipeptides v, ix and xiv (after removal of the Boc protecting group). After coupling of the groups to the dipeptides, the carboxylic acid and hydroxy protecting groups can be removed by standard basic conditions such as LiOH in a mixture of MeOH/THF/H 2 O.
- ethyl 4- iodobenzoate (xvi) can be converted to the acid xvii upon treatment with t-butyl acrylate in the presence of palladium catalyst and triphenylphosphine, followed by treatment with HCl to remove the t-butyl ester.
- FIG. 2 illustrates one method for preparing the compounds of the present invention on a resin. Briefly, an appropriately functionalized and protected (with protecting group (PG)) diarylamine can be attached to a solid support. Removal of the protecting group and addition of an amino acid, or mixture of amino acids, results xx. Subsequent removal of the protecting group and addition of a second amino acid, or mixture of amino acids results in the tethered dipeptide xxi. Again, removal of the protecting group and acylation of the free amino group with an acid provides the target compounds xxii.
- protecting group protecting group
- the compounds of the present invention can be evaluated for STAT binding activity using methods such as those described in co-pending application Ser. No. 09/053,003 (for STAT6 binding).
- Other assays for STAT binding can be found in, for example, U.S. Patent Nos. 5,618,693, 5,639,858 and 5,756,700
- compositions The compounds of the present invention can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms.
- the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally.
- the compounds described herein can be administered by inhalation, for example, intranasally.
- the compounds of the present invention can be administered topically, including transdermally.
- the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and either a compound of formula I or a pharmaceutically acceptable salt of a compound of formula I.
- pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- a solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier is a finely divided solid which is in a mixture with the finely divided active component.
- the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from 5% or 10% to 70% of the active compound.
- Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
- the term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active compoinent with or without other carriers, is surrounded by a carrier, which is thus in association with it.
- cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
- a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
- the active component is dispersed homogeneously therein, as by stirring.
- the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. Liquid forms are particluarly preferred for topical applications to the eye.
- liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
- Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
- liquid forms include solutions, suspensions, and emulsions.
- These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- the pharmaceutical preparation is preferably in unit dosage form, ⁇ n such form the preparation is subdivided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- the quantity of active component in a unit dose preparation may be varied or adjusted from about 2 mg to about 2000 mg, preferably about 5 mg to about 150 mg according to the particular application and the potency of the active component.
- the composition can, if desired, also contain other compatible therapeutic agents (e.g., antiviral agents such as acyclovir, ganciclovir, foscarnet and cidofovir).
- antiviral agents such as acyclovir, ganciclovir, foscarnet and cidofovir.
- the compounds utilized in the pharmaceutical method of the invention are administered at the initial dosage of about 0.05 mg/kg to about 20 mg/kg daily.
- a daily dose range of about 0.05 mg/kg to about 2 mg/kg is preferred, with a daily dose range of about 0.05 mg/kg to about 0.2 mg/kg being most preferred.
- the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
- Reagents and solvents used below can be obtained from commercial sources such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA).
- ⁇ -NMR spectra were recorded on a Narian Gemini 400 MHz ⁇ MR spectrometer. Significant peaks are tabulated in the order: number of protons, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet) and coupling constant(s) in Hertz.
- Electron Ionization (El) mass spectra were recorded on a Hewlett Packard 5989A mass spectrometer.
- Electrospray ionization (ESI) mass spectrometry analysis was conducted on a Hewlett-Packard 1100 MSD electrospray mass spectrometer using the HP 1100 HPLC for sample delivery. Normally the analyte was dissolved in methanol at O.lmg/mL and 1 microliter was infused with the delivery solvent into the mass spectromter which scanned from 100 to 1500 daltons. All compounds could be analyzed in the positive ESI mode, using 1:1 acetonitrile/water with 1% acetic acid as the delivery solvent. The compounds provided below could also be analyzed in the negative ESI mode, using 2mM NH4OAC in acetonitrile/water as delivery solvent.
- the HCl salt was dissolved in CH 2 C1 2 (100 mL) and to this solution was added Boc-L-t-butyl glycine (5.3 g, 27.6 mmol) and NMM (12.6 mL, 27.6 mmol). Five minutes later EDC (4.4 g, 27.6 mmol) and HOBT (3.1 g, 27.6 mmol) were added. The reaction was stirred for 8 h and then quenched with 10% aqueous citric acid. The aqueous layer was extracted with CH 2 C1 2 (2 x).
- the crude amide was dissolved in EtOH (80 mL) and ammonia was bubbled through the solution for 5 minutes. To this solution was added a catalytic amount of Raney nickel (50%) slurry in H 2 O). The reaction mixture was placed under a hydrogen atmosphere (50 psi) for 3 h, filtered through celite, and concentrated in vacuo to provide 2 g of the amine which was used without further purification.
- Ester 1.8 (500 mg, 0.53 mmol) was stirred in CH 2 C1 2 (20 mL) and El ⁇ NH (5 mL) for 12 h. The reaction mixture was concentrated in vacuo and triturated with CH 2 C1 2 (3 x). The solid was redissolved in CH 2 C1 2 (3 mL) and diluted with hexanes (25 mL). The resulting precipitate was removed by filtration and the filtrate was concentrated in vacuo to yield 440 mg of 1.9 which was used without further purification.
- Ester 2.4 (1.0 g, 1.7 mmol) was dissolved in a saturated solution of ammonia in methanol (25 mL) and stirred in a sealed tube for 42 h. The reaction was concentrated in vacuo and the residue purified by silica gel chromatography to afford 0.7 g (72%) of 2.5.
- the diphenyl amide was dissolved in CH 2 C1 2 / TFA (1 : 1, 40 mL) and stirred 30 minutes. The solvents were removed in vacuo to provide 3.1 g of the TFA salt which was used in the next reaction without further purification.
- the amine TFA salt was dissolved in CH 2 C1 2 (20 mL) and to this solution was added Boc-L-t-butylglycine (2.2 g, 9.5 mmol), EDC (1.8 g, 9.5 mmol), and Et 3 N (1.3 mL, 17.7 mmol). After 6 h, the reaction was quenched with 1 N HCl; the organic layer was washed with 1 N NaOH and brine, dried over MgSO 4 , and concentrated in vacuo. The material was purified by silica gel chromatography.
- the Boc group was removed by dissolving the material in CH 2 C1 2 / TFA (1:1, 10 mL). After 30 minutes, the solvents were removed in vacuo. The residue was dissolved in CH 2 C1 2 ; the organic layer was extracted with 1 N NaOH, dried over MgSO 4 , and concentrated in vacuo to provide 0.53 g (8% over 5 steps) of 3.5.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compounds and compositions are provided along with methods for their use as immunomodulators.
Description
STAT4 AND STAT6 BINDING DIPEPTIDE DERIVATIVES
FIELD OF THE INVENTION
The present invention relates generally to dipeptide compounds and, more particularly, to novel dipeptide analogs and compositions, their preparation and their use as modulators of the immune system.
BACKGROUND OF THE INVENTION
New therapeutic and diagnostic agents have begun to emerge from discovery efforts which use high-throughput screening directed to certain gene- specific transcription factors.
One family of transcription factors responsible for transmitting a signal to a cell's nucleus are the proteins known as Signal Transducers and Activators of Transcription (STATs; see: Darnell et al. (1994) Science 264: 1415; for review, see: e.g., Ihle et al. (1994) Trends Biochem. Sci. 19: 222; Ihle et al. (1995) Trends Genetics 11 : 69); and Horvafh et al. (1997) Curr Opn Cell Biol. 9:233). STATs are activated by contact with the phosphorylated cytokine receptor; activation results in the STAT polypeptides forming a dimer and entering the nucleus, where the STAT dimer binds to the regulatory region of a gene that is inducible by the particular cytokine. Binding of the activated STAT dimer triggers transcription of the gene.
The STAT polypeptides (STAT1, STAT2, STAT4, STAT5a, STAT5b, and STAT6) have molecular masses from 84-113 kDa. Each STAT protein contains a Src homology-2 (SH2) domain capable of recognizing one or more phosphotyrosine sequences in the cytoplasmic portion of the activated receptor (Shuai et al. (1993) Nature 366: 580). Additionally, each cytokine receptor is specific for a particular STAT protein, and each STAT activates transcription of certain genes, thereby providing two layers of specificity in cytokine-induced signalling.
STAT6 and STAT4 are two proteins that are intimately involved in regulation of immune responses. STAT4 transduces to the nucleus signals from the IL-12 receptor. IL-12 is involved in the development of a TH1 immune response (Kaplan et al. (1996) Nature 382: 174-177), which is part of an organism's defense against intracellular pathogens. IL-12 is also necessary for the T-cell-independent induction of the cytokine interferon (IFN)-γ, which is a key step in the initial suppression of bacterial and parasitic infections. Knockout mice which lack STAT4 were found to be defective in all IL-12 functions tested, including the induction of IFN-gamma, mitogenesis, enhancement of natural killer cytolytic function and TH1 differentiation (Thierfelder et al. (1996) Nature 382: 171-174).
IL-4 signals are transduced to the nucleus by STAT6. IL-4 is a key cytokine in the initiation of a TH2 immune response, and also activates B and T lymphocytes. STAT6-deficient mice were shown to be deficient in IL-4 activities (Kaplan et al. (1996) Immunity 4: 313-319; Takeda et al. (1996) Nature 380: 627-630; Shimoda et al. (1996) Nature 380: 630-633).
Because of the importance of STAT4 and STAT6 in modulating the immune response of an organism, both in response to infection and in undesirable conditions such as inflammation, allergic reactions, and autoimmune diseases, a need exists by which the clinician can diagnose, enhance or reduce STAT4 and STAT6 signals. Intervention at the STAT level would have significant advantages compared to previous approaches, which typically target the IL-4 or IL-12 cytokine itself, or the interaction of the cytokine with the receptor. Disruption of cytokine function itself can cause a variety of undesirable side effects. These can be avoided by intervening at the level of STAT-mediated signal transduction. However, identification of agents that can modulate STAT4 and STAT6-mediated signal transduction has heretofore been hampered by the lack of suitable assays. Recently, a new assay for identification of STAT6 and STAT4 signalling modulators was described (see, co-pending application Ser. No. 09/053,003, filed March 31, 1998). Assay of binding of STAT4 and STAT6 to their corresponding receptors, and identification of agents which increase or decrease the degree of such binding, has now led to the identification of
compounds which are useful in the diagnosis and treatment of various STAT- dependent conditions.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides compounds which are represented by the formula:
In the above formula, R1 and R2 are each independently selected from hydrogen, (CrC8)alkyl, (CrC8)heteroalkyl, aryl, aryl(C1-C8)alkyl, aryl(C C8)heteroalkyl, heteroaryl, heteroaryl(C,-C3)alkyl, and heteroaryl(C1-C8)heteroalkyl, with the proviso that at least one of R1 and R2 is selected from aryl, aryl(CI-C8)alkyl, aryl(C1-C8)heteroalkyl, heteroaryl, heteroaryl(C1-C8)alkyl and heteroary^C)- C8)heteroalkyl.
The symbol A1 represents a divalent L-α-amino acid or D-α-amino acid fragment or a fragment having the formula:
in which R3 is hydrogen or (CrC4) alkyl, and R4 and R5 are each independently selected from hydrogen, (CrC8)alkyl, (CrC8)heteroalkyl, aryl, aryl(CrC8)alkyl or aryl(CrC8)heteroalkyl, or R4and R5 can be individually combined with R3 to form a 5- , 6-, 7- or 8-membered ring containing from one to three heteroatoms.
The symbol A2 represents an L-α-amino acid or D-α-amino acid fragment or a fragment having the formula:
In the indicated formula, R6 is either hydrogen or (CrC4)alkyl; R7 and Rs are independently selected from hydrogen, (CrC8)alkyl, (CrC8)heteroalkyl, aryl, aryl(Cr C8)alkyl or aryl(C,-C8)heteroalkyl, or R7 and R8 can be combined with each other to form a 5-, 6-, 7- or 8-membered ring containing from zero to three heteroatoms. For each of the A1 and A2 groups above, the wavy line is meant to indicate the point of attachment to the remainder of the molecule. The amino acid fragments are those portions of an amino acid that remain after removal of the OH group from the carboxylic acid portion and a hydrogen atom from the α-amino portion.
The letter X represents a bond, a (C^ ) saturated or unsaturated alkyl linking group or a (CrC4) saturated or unsaturated heteroalkyl linking group.
The letter Y represents an acidic moiety, an isostere of an acidic moiety or an ester of an acidic moiety that can be converted to an acidic moiety in vivo. The acidic moiety (or ester or isostere) is attached to Ar either directly or with a spacer. Accordingly, Y can be represented as a group of formula:
-B'-Z' or -B^fZ'XZ2) wherein B1 is a bond or a divalent linking group and B2 is a trivalent linking group. The remaining groups, Z1 and Z2 are as follows:
Z1 represents a member selected from -CO2R9, -P(O)(OR9)(OR10), -P(O)(R9)(OR10), -S(O)2(OR9), -S(O)(OR9) and a carboxylic acid isostere. Similarly, the symbol Z2 represents a member selected from -CO2R9, -NHR11, -P(O)(OR9)(OR10), -P(O)(R9)(OR10), -S(O)2(OR9), -S(O)(OR9) and a carboxylic acid isostere. For the listed Z1 and Z2 groups, R9 and R10 each independently represent H, (CrC8)alkyl or (CrC8)heteroalkyl; and R11 represents (CrC8)alkyl.
The symbol Ar represents an aryl or heteroaryl group.
The compounds of the present invention are useful in compositions that further comprise a pharmaceutically acceptable excipient. Both the compounds and compositions of the present inventions are useful for the diagnosis and treatment (including prophylactic treatment) of conditions mediated through STAT signaling. Examples of conditions associated with STAT signaling include, but are not limited to: Thl -mediated conditions such as delayed-type hypersensitivity, contact dermatitis, uveitis, Crohn's disease, psoriasis and autoimmune diseases (typically associated with
STAT4 signaling); Th2-mediated diseases such as allergic rhinitis, asthma, scleroderma, eczema and conjunctivitis (typically associated with STAT6 signaling); proliferative disorders such as cancers (associated with STAT3 and/or STAT5 signaling); and STAT1 conditions which are similar to those described for STAT4, but typically observed in more acute situations such as acute transplant rejections. A variety of additional conditions associated with STAT signaling include atopic dermatitis, anaphylaxis, food or drug induced allergy, hypersensitivity reactions, alveolitis, Churg-Strauss syndrome, urticaria, angiodema, and systemic lupus erythematosus.
Other objects, features and advantages of the present invention will be apparent to one of skill in the art from the following detailed description and the claims.
BRIEF DESCRIPTION OF THE DRA WINGS
Figure 1 provides the structures for certain particularly preferred compounds of the present invention.
Figure 2 illustrates the solid-phase synthesis of compounds of the present invention.
Figure 3 provides structures for certain dicarboxylic acids that are useful in preparing compounds of formula I.
DETAILED DESCRIPTION OF THE INVENTION
Abbreviations
The following abbreviations are used herein: Ac, acetyl; Bn, benzyl; Bz, benzoyl; Boc, t-butoxycarbonyl; EDC, l-(3-Dimethylaminopropyι)-3- ethylcarbodiimide hydrochloride; HOBT, hydroxybenzotriazole; NMM, N- methylmorpholine; DMF, dimethylformamide; EtOAc, ethyl acetate; HBTU, 2-(lH- benzotriazole- 1 -yl)- 1 , 1 ,3 ,3 -tetrametliyluronium hexafluorophosphate; THF, tefrahydrofuran; FMOC, fluorenylmethyloxycarbonyl; TFA, trifluoroacetic acid; Me,
methyl; Et, ethyl; Ph, phenyl; STAT, signal transducers and activators of transcription; rt, room temperature.
Definitions:
The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i. e. Cj-Cio means one to ten carbons). Examples of saturated hydrocarbon radicals include groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)ethyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isoρentenyl, 2- (butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3- butynyl, and the higher homologs and isomers. The term "alkylene" by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified by -CH2CH2CH2CH2-. Typically, an alkyl or alkylene group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
The terms "alkoxy," "alkylamino" and "alkylthio" refer to those groups having an alkyl group attached to the remainder of the molecule through an oxygen, nitrogen or sulfur atom, respectively. Similarly, the term "dialkylamino" is used in a conventional sense to refer to -NR'R" wherein the R groups can be the same or different alkyl groups.
The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of
O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. The heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule. Examples include -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, - CH2-CH2-S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N- OCH3, and -CH=CH-N(CH3)-CH3. Up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. Also included in the term "heteroalkyl" are those radicals described in more detail below as "heterocycloalkyl." The term "heteroalkylene" by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified by -CH2-CH2-S-CH2CH2- and -CH2- S-CH2-CH2-NH-CH2-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini. Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied.
The term "acyl" refers to those groups derived from an organic acid by removal of the hydroxy portion of the acid. Accordingly, acyl is meant to include, for example, acetyl, propionyl, butyryl, decanoyl, pivaloyl, benzoyl and the like.
The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl", respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include 1 -(1,2,5,6-tetrahydropyridyl), 1 -piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3- yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine
atom. Additionally, terms such as "fluoroalkyl," are meant to include monofluoroalkyl and polyfluoroalkyl.
The term "aryl," employed alone or in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) means, unless otherwise stated, an aromatic substituent which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently. The term "heteroaryl" is meant to include those aryl rings which contain from zero to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. The "heteroaryl" groups can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1 -pyrrolyl, 2- pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4- oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2- thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3- pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2- benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5- quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl ring systems are selected from the group of acceptable substituents described below. The term "arylalkyl" is meant to include those radicals in which an aryl or heteroaryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) or a heteroalkyl group (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(l- naphthyloxy)propyl, and the like).
Each of the above terms (e.g., "alkyl," "heteroalkyl" and "aryl") are meant to include both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.
Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be a variety of groups selected from: -OR', =O, =NR', =N-OR\ -NR'R", -SR', -halogen, - SiR'R"R'", -OC(O)R\ -C(O)R\ -CO2R\ CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R'", -NR"C(O)2R', -NH-C(NH2)=NH, -NR'C(NH2)=NH,
-NH-C(NH2)=NR', -S(O)R', -S(O)2R\ -S(O)2NR'R", -CN and -NO2in a number ranging from zero to (2N+ 1), where N is the total number of carbon atoms in such radical. R', R" and R'" each independently refer to hydrogen, unsubstituted(Cr C8)alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl-(C1-C4)alkyl groups. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R" is meant to include 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups such as haloalkyl (e.g., -CF3 and -CH2CF3) and acyl (e.g., -C(O)CH3, -C(O)CF3, - C(O)CH2OCH3, and the like).
Similarly, substituents for the aryl groups are varied and are selected from: -halogen, -OR', -OC(O)R\ -NR'R", -SR\ -R', -CN, -NO2- -CO2R\ - CONR'R", -C(O)R'3 -OC(O)NR'R", -NR"C(O)R\ -NR"C(O)2R\ -NR'- C(O)NR"R'"5 -NH-C(NH2)=NH, -NR'C(NH2)=NH, -NH-C(NH2)=NR', -S(O)R', - S(O)2R', -S(O)2NR'R", -N3, -CH(Ph)2, perfluoro(C,-C4)alkoxy, and perfluoro(Cr C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R" and R'" are independently selected from hydrogen, (CrC8)alkyl and heteroalkyl, unsubstituted aryl, (unsubstituted aryl)-(Cr C4)alkyl, and (unsubstituted aryl)oxy-(CrC4)alkyl.
Two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CH2)q-U-, wherein T and U are independently -NH-, -O-, -CH2- or a single bond, and the subscript q is an integer of from 0 to 2. Alternatively, two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula -A-(CH2)r-B-, wherein A and B are independently -CH2-3 -O-, -NH-, -S-, -S(O , -S(O)2-, -S(O)2NR'- or a single bond, and r is an integer of from 1 to 3. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula -(CH2)s-X-(CH2)t-, where s and t are independently integers of from 0 to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O)2-, or -S(O)2NR'-. The
substituent R' in -NR'- and -S(O)2NR'~ is selected from hydrogen or unsubstituted (CrC6)alkyl.
As used herein, the term "heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).
The term "pharmaceutically acceptable salts" is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, oxalic, maleic, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S.M., et al, "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1911, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in
certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
In addition to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.
The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (125I) or carbon-14 (14C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
Still further, the compounds of the present invention can be conjugated to easily-detectable groups, such as fluorescein or biotin, for use as reagents or diagnostic tools. Additionally, such tagged compounds can be further attached to a
solid support (e.g., bead, resin or microtiter plate)and used in binding experiments to discover other compounds that interact with STAT6.
General:
The present invention provides compounds, compositions and methods for the inhibition or treatment of conditions or disorders modulated by the STAT transcription factors, particularly STAT4 and STAT6. Additionally, the compounds are useful for the diagnosis of conditions dependent on STAT signaling. Without intending to be bound by a theory, it is believed that certain compounds of the present invention block interaction between phosphorylated tyrosine residues in the IL-4 receptor and the SH2 domain of STAT6. In this manner, phosphorylation (i.e., activation) of STAT6 by IL-4-receptor-associated kinases is prevented. It is also believed that the compounds exert their effect by interfering with the dimerization of STAT6 monomers that is required before the STAT6 dimer can bind to the STAT6- dependent genes and initiate transcription of, for example, germline epsilon transcript. In view of this transcriptional control, the compounds, compositions and methods of the present invention will be useful in treating (suppressing or inhibiting) the full spectrum of immune disorders which require transcriptional activation by STAT6 dimer, including allergic conditions (e.g., allergic rhinitis, asthma, atopic dermatitis, contact dermatitis, anaphylaxis, food or drug induced allergy, conjunctivitis, uveitis, hypersensitivity reactions, alveolitis and psoriasis), Churg-Strauss syndrome, delayed- type hypersensitivity, urticaria, angiodema, eczema, scleroderma, and systemic lupus erythematosus.
Embodiments of the Invention:
Compounds
In one aspect, the present invention provides compounds which are represented by the the formula:
In the above formula, R1 and R2 are each independently selected from hydrogen, (CrC8)alkyl, (CrC8)heteroalkyl, aryl, aryl(C1-C8)alkyl, aryl(Cr C8)heteroalkyl, heteroaryl, heteroaryl(CrC8)alkyl and heteroary^Cj-C^heteroalkyl, with the proviso that at least one of R1 and R2 is selected from aryl, aryl(Cι-C8)alkyl, aryl(C1-C8)heteroalkyl, heteroaryl, heteroaryl(C1-C8)alkyl and heteroaryl(Cr C8)heteroalkyl.
In one group of embodiments, R1 is selected from (CrC8)alkyl and (Cr C8)heteroalkyl, and R2 is selected from aryl, aryl(Cι-C8)alkyl, and ary^C,- C8)heteroalkyl. More preferably, R2 is selected from aryl and aryl(C,-C8)alkyl. Still more preferably, R1 is selected from (CrC4)alkyl and R2 is substituted or unsubstituted aryl. Most preferred are those embodiments in which R2 is an optionally substituted phenyl or optionally substituted benzyl group.
In another group of embodiments, R1 and R2 are each selected from aryl, aryl(CrC8)alkyl and aryl(C1-C8)heteroalkyl. In one group of particularly preferred embodiments, R1 and R2 are each independently an optionally substituted phenyl group. In still other preferred embodiments, R1 and R2 are both optionally substituted benzyl groups. In yet other preferred embodiments, R1 is an optionally substituted phenyl group and R2 is an optionally substituted benzyl group. With the embodiments described herein, the substituents on the aryl rings can be any of those substituents described above in the definitions section. Preferably, however, the substituents are selected from -CONH2, -CH2NHCO-(4-nitro-2-pyrazolyl), -NHCONH2, -C(NH)NH2, -CONHPh, -CH2NH2, -CH2NHCO-CH=CH-(3- nitrophenyl), -CH3, -Cl, -Br, -I, -CO2H, -CO2CH3, -OCH3, -OH, -Ph, -OPh, -CON(CH3)2, -C(CH3)3, -CH2NHAc, -CN, -CH2NHCO-CH=CH-(4-pyridyl), and the like. In certain preferred embodiments, R1 and R2 are phenyl or benzyl groups and the additional substituents occupy positions on the benzene ring that are meta or para to the positions at which the benzene rings are attached to the remainder of the molecule.
In formula (I), the symbol A1 represents a divalent L-α-amino acid or D-α-amino acid fragment or a fragment having the formula:
in which R3 is hydrogen or ( -Q alkyl, and R4 and R5 are each independently selected from hydrogen, ( -C^alkyl, ( -C^heteroalkyl, aryl, aryl(CrC8)alkyl or
or R4 and R5 can be individually combined with R3 to form a 5- , 6-, 7- or 8-membered ring containing from one to three heteroatoms. One of skill in the art will understand that when A1 is described as an amino acid or an amino acid fragment, what is meant is a residue of the amino acid that typically remains upon incorporation of the amino acid into a peptide or other similar linear array or polymer. For example, if A1 is " alanine," the term is meant to refer to that fragment that is typically incorporated into a peptide or protein (i.e., -NH-CH(CH3)-C(O)-). In certain preferred embodiments, A1 is an amino acid selected from 2-aminoisobutyric acid, sarcosine, norvaline, homoserine, citrulline, norleucine, 2,3-diaminopropionic acid, methionine oxide, methionine dioxide, penicillamine, homoleucine, ornithine, 3H- dehydroproline, 2-methylproline, homoproline, 5-phenylproline, 4-chloroproline, proline, tyrosine, serine, methionine and alanine.
In another group of preferred embodiments, A1 is a fragment having the formula above in which R5 is hydrogen and R3 and R4 are combined to form a 5-, 6-, or 7-membered ring containing from one to three heteroatoms. More preferably, R3 and R4 are combined to form a 5-membered ring containing from one to three heteroatoms. In other preferred embodiments, A1 is a fragment selected from
in which E1, E2, E3 and E4 each independently represent C, N, S or O, with the proviso that the 5-, 6- or 7-membered ring contains no more than three heteroatoms as ring members. When any of E1 to E4 are C or N, the remaining valences can be occupied by bonds to hydrogen, aryl,
(CrC8)heteroalkyl, aryl(CrC8)alkyl,
aryl(C1-C8)heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl. Preferably, when any of E1 to E4 are N, the remaining valence is occupied by (CrC8)alkyl, most preferably substituted (C,-C8)alkyl (e.g., acetyl, propionyl and the like).
In one group of particularly preferred embodiments, A1 is represented by the formula:
cry in which W1 represents H, -OR12 or -NR12R13. The R12 and R13 groups independently represent hydrogen, aryl, (C1-C8)alkyl, ( -C^heteroalkyl, aryl(C,-C8)alkyl, aryl(C,- C8)heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl. Preferably, W1 is - NHCOCH3, -NHCOCH2CH2NHAc, -NH2, -NH-tosyl, -NHCOPh, -NHCOCH(CH3)2, -NHSO2CH3, -NHCO2CH2Ph, -N(CH3)2, and -N(CH2Ph)2. The W1 group can have either a cis or trans orientation relative to the carbonyl group at the 2-position of the pyrrolidine ring, or can exist as a mixture of isomers at the center bearing the W1 group.
The symbol A2 represents an L-α-amino acid or D-α-amino acid fragment or a fragment having the formula:
In the indicated formula, R6 is either hydrogen or (CrC4)alkyl; R7 and R8 are independently selected from hydrogen, (C1-C8)alkyl, (C1-C8)heteroalkyl, aryl, aryl(C,-
C8)alkyl or aryl(Cj-C8)heteroalkyl, or R7 and Rs can be combined with each other to form a 5-, 6-, 7- or 8-membered ring containing from zero to three heteroatoms. In preferred embodiments, A2 represents an amino acid selected from norvaline, homoserine, cyclohexylalanine, norleucine, diaminopropionic acid, methionine oxide, homoleucine, ornithine, tert-butylglycine, 3 -methoxy valine, allothreonine, valine, tlireonine, leucine, isoleucine, lysine and methionine. More preferably, A2 is selected from L- valine, L-leucine, L-lysine, L-methionine. L-threonine, L-isoleucine and L- tert-butylglycine. Most preferably, A2 is L-valine or L-tert-butylglycine. As with the
definition of A1, one of skill in the art will understand that when A2 is described as an amino acid or an amino acid fragment, what is meant is a residue of the amino acid that typically remains upon incorporation of the amino acid into a peptide or other similar linear array or polymer.
In formula (I), the symbol X represents a bond, a (CrC4) saturated or unsaturated alkyl linking group or a (C,-C4) saturated or unsaturated heteroalkyl linking group. Preferably, X is -OCH2-, -CH2CH2-, -CH=CH-, -CH=C(CH3)-, -C≡C-, -NHCH2-, -N(R)CH2CH2-, -N=CH-, or -CH=N- in which R represents hydrogen or a lower alkyl group (e.g., methyl, ethyl, acetyl, propyl and the like). Most preferably, X represents a trans -CH=CH- linking group, a trans -CH=C(CH3)- linking group, or a -C≡C- linking group.
The symbol Ar represents an aryl or heteroaryl group. A variety of aryl and heteroaryl groups are useful in the present invention. Preferred aryl and heteroaryl groups include benzene, naphthalene, pyridine, furan, imidazole, pyrazole, thiophene. biphenyl, dihydronaphthalene, 1,2,3-triazole and pyrazine. Particularly preferred is benzene in which the X and Y groups are attached to the benzene ring at positions para to each other. In another group of embodiments, Ar is benzene, X and Y are attached at positions para to each other, and the benzene ring is further substituted with at least one additional substituent selected from -halogen, -OR', - OC(O)R\ -NR'R", -SR', -R', -CN, -NO2, -CO2R', -CONR'R", -OC(O)NR'R", - NR"C(O)R', -NR"C(O)2R', perfluoro(CrC4)alkoxy, and perfluoro(C1-C4)alkyl, where R' and R" are independently selected from hydrogen, (CrC8)alkyl, (C,-C8)heteroalkyl, and unsubstituted aryl.
The letter Y represents an acidic moiety, an isostere of an acidic moiety or an ester of an acidic moiety that can be converted to an acidic moiety in vivo. The acidic moiety (or ester or isostere) is attached to Ar either directly or with a spacer. Accordingly, Y can be represented as a group of formula:
-B1-Z1 or -B2-(Z1)(Z2) wherein B1 is a bond or a divalent linking group and B2 is a trivalent linking group. The terms " divalent linking group" and "trivalent linking group" are meant to
include groups having two and three available valences respectively, for covalent attachment to Ar, Z1 and Z2. The linking groups typically serve as scaffolds to preserve a certain orientation or spacing between Z1 or Z2 and Ar. As a result, the linking groups will typically comprise from one to eight carbon atoms. Optionally, from one to three of the carbon atoms will be replaced with a heteroatom (e.g., O, N S, Si). For example, B1 can be a bond, -O-, -CH2-, -CHF-, -CH(OH)-, -CF2-, -OCH2-, -CH2CH2-, -CH=CH-, -NH-CH2-, -N=CH-, -CF2CF2-, -OCF2-, -OCHF- or -CHF-CHF-. As already noted, B1 can be a longer homolog of the above linking groups, for example a three-carbon or four-carbon alkylene group which is optionally substituted with additional alkyl groups, halogen atoms or heteroatoms. Trivalent (B2) linking groups that are useful in the present invention include, for example,
— C I H • — C-C IH . — C H-C I-CH, , — C I-OH an Λd — N=C /' •
I HH in I I x
The symbol Z1 represents a member selected from -CO2R9, -P(O)(OR9)(OR10), -P(O)(R9)(OR10), -S(O)2(OR9), -S(O)(OR9) and a carboxylic acid isostere. Similarly, the symbol Z2 represents a member selected from -CO2R9, -NHR11, -P(O)(OR9)(OR10), -P(O)(R9)(OR10), -S(O)2(OR9), -S(O)(OR9) and a carboxylic acid isostere. For the listed Z1 and Z2 groups, R9 and R10 each independently represent H, (CrC8)alkyl, aryl or
and R11 represents (C,-C8)alkyl, preferably a substituted (C,-C8)alkyl group (e.g., acetyl, propionyl, butanoyl, and the like).
In one group of preferred embodiments, Z1 and Z2 are selected from -CO2H, -PO3H2, -P(O)(CH3)(OH) and a carboxylic acid isostere. A number of carboxylic acid isosteres are known to those of skill in the art, including, for example, tetrazole, amidotetrazole, methanesulfonamide, 3-isoxazolone, isoxazolidine-3,5- dione and 1,2,4-triazole (see, e.g., Ornstein, et al, J. Med. Chem. 39:2232-2244 (1996) and Lipinski, Ann. Reports Med. Chem. 21:283-291 (1986). Most preferably, Z1 and Z2 are selected from -CO2H and -PO3H2. For those embodiments in which Z1 is a-CO2H or -PO3H2 (or a salt thereof), B1 will preferably be a bond, -O-, -CH2-,
-CHF-, -CH(OH)-, -CF2-, -OCH2-, -CH2CH2-, -CH=CH-, -NH-CH2-, -CF2CF2-, -OCF2-, -OCHF- or -CHF-CHF-.
In another group of preferred embodiments, 7) and Z2 are selected from -CO2R9, -P(O)(OR9)(OR10) and -P(O)(R9)(OR10), in which R9 and R10 are each independently selected from (CrC8)alkyl and (CrC8)heteroalkyl. Suitable alkyl and heteroalkyl groups include, for example, methyl, ethyl, propyl, isopropyl, tert-butyl, sec-butyl, isobutyl, methoxymethyl, methoxyethyl, acetoxymethyl, propionyloxymethyl and pivaloyloxymethyl (-CH2OC(O)C(CH3)3).
The above recitation provides general description of the embodiments and preferred embodiments for portions of the compounds of the present invention. Certain combinations of the components are particularly preferred. For example, in one particularly preferred embodiment, the compounds have the formula:
wherein the symbol W1 represents hydrogen, -OR12 or -NR12R13; the symbols W2, W3 and W4 each independently represent hydrogen, halogen, -R14, -CO2R14, -OR14, -NR14R15 or -CONR14R15; wherein each of R12, R13, R14 and R15 independently represent hydrogen, aryl, (CrC8)alkyl, ( -C^heteroalkyl, aryl(CrC8)alkyl, aryl(C,- C8)heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl; and the symbol W5 represents a hydrogen or (C,-C8)alkyl. The remaining symbols, R7 and Y can be any of the groups defined for general formula (I), above. In one group of preferred embodiments, R7 is selected from ethyl, isopropyl, isobutyl, tert-butyl, sec-butyl, cyclohexylmethyl, and 2-methoxy-2-propyl. Also preferred are tliose embodiments in which Y is selected from:
_C02H ,
In another group of particularly preferred embodiments, the compound has the formula:
wherein the symbol W1 represents hydrogen, -OR12 or -NR12R13; the symbols W2 and W3 each independently represent hydrogen, halogen, -R14, -CO2R14, -OR14, -NR14R15 or -CONR14R15; wherein each of R12, R13, R14 and R15 independently represent hydrogen, aryl, (CrC8)alkyl, (C1-C8)heteroalkyl, aryl(CrC8)alkyl, aryl(CrC8)heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl; the symbol W5 represents a hydrogen or (C1-C8)alkyl; and the symbol W6 represents a
The remaining symbols, R7 and Y can be any of the groups defined for general formula (I), above. Preferred groups for the symbols noted and those defined above are the same as the preferred groups provided for formula Ila.
In yet another group of particularly preferred embodiments, the compound has the formula:
wherein the symbol W1 represents hydrogen, -OR12 or -NR12R13; the symbols W2, W3 and W4 each independently represent hydrogen, halogen, -R14, -CO2R14, -OR14, -NR14R15 or -CONR14R15; wherein each of R12, R13, R14 and R15 independently represent hydrogen, aryl, (C1-C8)alkyl, (CrC8)heteroalkyl,
aryl(C C8)heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl; and the symbol W5 represents a hydrogen or (C,-C8)alkyl. The remaining symbols, R7 and Y can be any of the groups defined for general formula (I), above. Preferred groups for the symbols noted and those defined above are the same as the preferred groups provided for formula Ila.
Structural formulae for some of the most preferred compounds of the present invention are provided in Figure 1.
The compounds of the present invention are useful in therapeutic as well as prophylactic and diagnostic applications, and are also useful in drug discovery research. Accordingly, the present invention provides suitably modified derivatives of the above compound in such a manner that their interaction with a STAT6 molecule (or fragment thereof) can be easily detected by physical or chemical means. The present invention further provides compositions containing the above compounds and pharmaceutically acceptable excipients or diagnostically acceptable excipients. Still further, the invention provides methods of treating conditions or diseases, particularly those mediated by STAT6 signaling. Such conditions or diseases include allergic conditions (e.g., allergic rhinitis, asthma, atopic dermatitis, contact dermatitis, anaphylaxis, food or drug induced allergy, conjunctivitis, uveitis, hypersensitivity
reactions, alveolitis and psoriasis), Churg-Strauss syndrome, delayed-type hypersensitivity, urticaria, angiodema, eczema, scleroderma, and systemic lupus erythematosus. In addition to treatments for existing conditions, the present invention also provides methods for prophylactic treatments to prevent the onset of the above- noted disorders in patients.
In still other embodiments, the invention provides methods of treating conditions such as those above, by administering to a subject in need of such treatment a therapeutic regimen comprising a compound provided herein, in combination with another agent such as, for example, loratidine, fluticasone propionate, beclametasone diproprionate, budesonide, salmeterol xinafoate, ipratropium bromide, fexofenadine hydrochloride, cetirizine dihydrochloride, triamcinolone acetonide, cromolyn, salbutamol, montelukast sodium, ketotifen hydrogen fumarate, formoterol, zafirlukast, momefasone furoate, azelastine hydrochloride, epinastine, seratrodast, captropril, rampril, zofenopril, colchicine, enalapril, lisinopril, trandolapril, gold sodium thiomalate, calcipotriene, cyclosporine, vinblastine and dapsone.
In some cases, when combinations of therapeutic agents are used, the amount of each agent administered may be less than the amount required when the agent is used alone. In some embodiments, the agents are synergistic with the compounds provided herein and can be used in amount that are less than one-half of the normal efficacious dose. Additionally, when therapy is provided using a combination of agents, the administration of the agents can be simultaneous or sequential. In instances wherein administration is sequential, the agents can be administered in any order and the periods between administration of a first and second agent can be minutes, hours, days, weeks, or months.
Preparation of the Compounds
The compounds of the present invention can be prepared as generally described below and depicted in Schemes 1-4. One of skill in the art will appreciate that certain additional steps (e.g., protection and deprotection of certain labile substituents) may be necessary, but are easily accomplished by the skilled artisan.
Scheme 1 provides a general outline for the synthesis of compounds in which A1 is an L-α-amino acid (alanine), A2 is an L-α-amino acid (valine), and R1 and R2 are both aryl groups.
As shown in Scheme 1, treatment of Boc-protected L-alanine (i) with methyl 4-aminobenzoate (ii) in the presence of EDC provides amide iii. Treatment of iii with triphenylbismuth and copper(II) acetate provides diaryl amide iv. Removal of the Boc protecting group from iv and subsequent coupling with Boc-valine, followed by conversion of the methyl ester group to an amide (with ammonia) provides dipeptide v. Again, the removal of the Boc protecting group and acylation of the free amine with the acid vi, furnishes vii after ester hydrolysis (HC1, dioxane).
SCHEME 1
Bi(Ph)3 Cu(OAc)2
The general methodology outlined in Scheme 1 can be used with essentially any amino acids. For example, compounds of the present invention can be prepared by substituting Boc-alanine (i) with suitably protected forms of any of the following non-limiting examples: 2-aminoisobutyric acid, sarcosine, norvaline, homoserine, citrulline, norleucine, 2,3 -diaminopropionic acid, methionine oxide, methionine dioxide, penicillamine, homoleucine, ornithine, 3H-dehydroproline, 2- methylproline, homoproline, 5-phenylproline, 4-chloroproline, proline, tyrosine, serine, and methionine. Similarly, Boc-valine can be substituted with suitably
protected forms of, for example, norvaline, homoserine, cyclohexylalanine, norleucine, diaminopropionic acid, methionine oxide, homoleucine, omithine, tert- butylglycine, 3 -methoxy valine, allothreonine, threonine, leucine, isoleucine, lysine and methionine. Similarly, the acid vi can be replaced in the synthesis scheme with a variety of other acids (see, for example, the acids depicted in Scheme 4 and those prepared in Example 3.3).
SCHEME 2
PhCH2Br NaH
IX III
3) HCl, dioxane
Scheme 2 illustrates a synthesis outline for the preparation of compounds in which R1 is a substituted phenyl and R2 is benzyl (or a substituted benzyl). In this scheme, synthesis begins as outlined in Scheme 1 to provide iii. Conversion of iii to amide viii can be accomplished by treating iii with sodium hydride and benzyl bromide. The remaining steps are essentially the same as those steps described in Scheme 1. Thus, removal of the Boc group in viii, followed by attachment of Boc-leucine and conversion of the methyl ester to an amide (with ammonia) results in formation of ix. Conversion of ix to x follows those steps which were outlined for the conversion of v to vii.
SCHEME 3
XIII
and 1 ,4-phenylenediacrylic acid
Scheme 3 provides a synthesis outline for compound in which R1 and R2 are each benzyl. One of skill in the art will understand that the method provided will be applicable to other arylalkylamines and substituted arylalkylamines. As illustrated in Scheme 3, condensation of benzaldehyde and benzylamine, and reduction of the Schiff base initially produced, yields dibenzylamine xii. Acylation of
xii with Boc-proline provides xiii, which can be deprotected and acylated with Boc-t- butylglycine to provide xiv. Deprotection of xiv and acylation with 1,4- phenylenediacrylic acid provides the target compound xv.
Substitution patterns on the benzene ring portions of R1 and R2 can be varied by starting the synthesis outlined in Scheme 3 with alternative substituted benzaldehydes and substituted benzylamines. Coupling the resultant dibenzylamine derivative with various amino acids (or alternatively, a dipeptide) and acylation of the N-terminous provides compound of the present invention.
The starting materials used in the synthesis schemes above are generally commercially available or can be prepared using standard synthetic methodology. Scheme 4 provides reaction schemes for preparing carboxylic acids that effectively add Y-Ar-X-C(O)- to the dipeptides v, ix and xiv (after removal of the Boc protecting group). After coupling of the groups to the dipeptides, the carboxylic acid and hydroxy protecting groups can be removed by standard basic conditions such as LiOH in a mixture of MeOH/THF/H2O. For example, in Scheme 4, ethyl 4- iodobenzoate (xvi) can be converted to the acid xvii upon treatment with t-butyl acrylate in the presence of palladium catalyst and triphenylphosphine, followed by treatment with HCl to remove the t-butyl ester.
SCHEME 4
XVIII XIX
Combinatorial and Solid Phase approaches Preparation of certain compounds can be accomplished using combinatorial methodology or solid phase synthesis. Figure 2 illustrates one method for preparing the compounds of the present invention on a resin. Briefly, an appropriately functionalized and protected (with protecting group (PG)) diarylamine can be attached to a solid support. Removal of the protecting group and addition of an amino acid, or mixture of amino acids, results xx. Subsequent removal of the protecting group and addition of a second amino acid, or mixture of amino acids results in the tethered dipeptide xxi. Again, removal of the protecting group and acylation of the free amino group with an acid provides the target compounds xxii. Depending on the nature of the protecting groups, a variety of automated synthesis formats can also be used for preparing the present compounds. A review of the methods (e.g., light-directed methods, pin-based methods, flow-channel methods and the like) can be found in U.S. Patent Nos. 5,556,752 and 5,624,711.
Other useful methods for preparing the target compounds are those that obviate the need for certain protection and deprotection steps. For example, in Figure 2, use of a symmetrical aryl dicarboxylic acid makes protection and deprotection of the distal (unreactive site) carboxylic acid unnecessary. Examples of commercially available dicarboxylic acids are provided in Figure 3.
Analysis of the Compounds
The compounds of the present invention can be evaluated for STAT binding activity using methods such as those described in co-pending application Ser. No. 09/053,003 (for STAT6 binding). Other assays for STAT binding can be found in, for example, U.S. Patent Nos. 5,618,693, 5,639,858 and 5,756,700
Formulation and Administration of the Compounds (Compositions) The compounds of the present invention can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or
intraperitoneally. Also, the compounds described herein can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered topically, including transdermally. Accordingly, the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and either a compound of formula I or a pharmaceutically acceptable salt of a compound of formula I.
For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
The powders and tablets preferably contain from 5% or 10% to 70% of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active compoinent with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. Liquid forms are particluarly preferred for topical applications to the eye. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The pharmaceutical preparation is preferably in unit dosage form, ϊn such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
The quantity of active component in a unit dose preparation may be varied or adjusted from about 2 mg to about 2000 mg, preferably about 5 mg to about 150 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents (e.g., antiviral agents such as acyclovir, ganciclovir, foscarnet and cidofovir).
In therapeutic use as immunomodulators, the compounds utilized in the pharmaceutical method of the invention are administered at the initial dosage of about 0.05 mg/kg to about 20 mg/kg daily. A daily dose range of about 0.05 mg/kg to about 2 mg/kg is preferred, with a daily dose range of about 0.05 mg/kg to about 0.2 mg/kg being most preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
The following examples are offered by way of illustration and are not intended to limit the scope of the invention.
EXAMPLES
Reagents and solvents used below can be obtained from commercial sources such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA). Η-NMR spectra were recorded on a Narian Gemini 400 MHz ΝMR spectrometer. Significant peaks are tabulated in the order: number of protons, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet) and coupling constant(s) in Hertz. Electron Ionization (El) mass spectra were recorded on a Hewlett Packard 5989A mass spectrometer. Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parentheses). Electrospray ionization (ESI) mass spectrometry analysis was conducted on a Hewlett-Packard 1100 MSD electrospray mass spectrometer using the HP 1100 HPLC for sample delivery. Normally the analyte was dissolved in methanol at O.lmg/mL and 1 microliter was infused with the delivery solvent into the mass spectromter
which scanned from 100 to 1500 daltons. All compounds could be analyzed in the positive ESI mode, using 1:1 acetonitrile/water with 1% acetic acid as the delivery solvent. The compounds provided below could also be analyzed in the negative ESI mode, using 2mM NH4OAC in acetonitrile/water as delivery solvent.
EXAMPLE 1
This example illustrates the synthesis of compound 1.
1.1 Preparation of compound 1.1
1.1
To 4-bromomandelic acid (10.0 g, 43.3 mmol) in benzene / methanol (9:1, 200 mL) at 0 °C was added dropwise (trimethylsilyl)diazomethane (2.0 M in hexanes, 22 mL, 44 mmol). After 20 minutes, the solution was concentrated in vacuo to afford a colorless oil which was used without further purification.
To a solution of the crude methyl ester in acetic anhydride (100 mL) was added NaOAc (5.0 g, 61 mmol). The resulting solution was stirred for 3 hours, diluted with H2O, and stirred for an additional 48 h. The reaction mixture was diluted with CH2C12, the two layers were separated, and the organic layer was washed with H2O (3 x). The organic layer was dried over MgSO4, filtered, and concentrated in
vacuo to afford a thick oil. Trituration of the oil with toluene (2 x) provided 9.0 g of a white solid.
To a solution of the white solid (9.0 g) and t-butyl acrylate (13.7 mL, 93 mmol) in Et3N (60 mL) and toluene (5 mL) was added Pd(OAc)2 (0.7 g, 3.1 mmol) and tri-o-tolylphosphine (1.0 g, 3.2 mmol). The solution was heated to reflux and. stirred for 3 h. The reaction was cooled, filtered through celite, concentrated in vacuo, and purified by flash chromatography to yield 9.0 g (62% over three steps) of 1.1.
1.2 Preparation of compound 1.2
1.2
To a solution of 1.1 (9.0 g, 26.5 mmol) in CH2C12 (60 mL) at 0 °C was added TFA (40 mL) dropwise over 15 minutes. The resulting solution was warmed to rt and stirred for 1.5 h. The reaction was concentrated in vacuo and triturated with CH2C12 (4 x). The residue was dissolved in CH2C12 (50 mL) and hexanes (700 mL) was added dropwise resulting in the precipitation of a white solid. Collection of the white solid by filtration yielded 6.0 g (81%) of 1.2.
1.3 Preparation of compound 1.3
1.3
Methyl 4-aminobenzoate (9.1 g, 60 mmol) and Boc-L-proline (15 g, 70 mmol) were dissolved in CH2C12. To this solution was added NMM (33 mL, 300 mmol) and EDC (19.2 g, 100 mmol). After 16 h, the reaction was quenched with 10% aqueous citric acid. The aqueous layer was extracted with CH2C12 (3 x); the organic layer was extracted with saturated NaHCO3 (2 x), dried over MgSO4, and concentrated in vacuo to afford 19 g of a yellow oil. Purification by silica gel chromatography provided 16 g (76%) of 1.3 as a pale yellow foam.
1.4 Preparation of compound 1.4
1.4
To ester 1.3 (8 g, 23 mmol) in EtOAc (150 mL) was added HCl (4 M in dioxane, 50 mL, 200 mmol). After 45 minutes, the reaction was concentrated in vacuo. The residue was triturated with CH2C12 and the HCl salt produced was used without further purification.
The HCl salt was dissolved in CH2C12 (100 mL) and to this solution was added Boc-L-t-butyl glycine (5.3 g, 27.6 mmol) and NMM (12.6 mL, 27.6 mmol). Five minutes later EDC (4.4 g, 27.6 mmol) and HOBT (3.1 g, 27.6 mmol) were added. The reaction was stirred for 8 h and then quenched with 10% aqueous citric acid. The aqueous layer was extracted with CH2C12 (2 x). The combined organic portions were washed with saturated NaHCO3, dried over MgSO4, and concentrated in vacuo to provide 10 g of a yellow oil that was purified by filtering through silica gel to yield 6 g (57%) of 1.4 as a yellow foam.
1.5 Preparation of compound 1.5
To a 0 °C solution of ester 1.4 (4.61 g, 10.0 mmol) and a-bm o-p- tolunitrile in CH2C12 / DMF (1 : 1 , 100 mL) was added NaH (60% dispersion in mineral oil, 433 mg, 10.8 mmol). The reaction was warmed to rt and stirred for 1.5 h. The mixture was concentrated in vacuo and the residue was partitioned between CH2C12 and aqueous NH4C1. The aqueous layer was extracted with CH2C12 (2 x). The combined organic layer was dried over MgSO4 and concentrated in vacuo to provide 5 g of a yellow oil. Purification by silica gel chromatography afforded 3.16 g (55%) of 1.5 as a white foam.
1.6 Preparation of compound 1.6
To ester 1.5 (600 mg, 1.0 mmol) in methanol (2 mL) was added ammonia (40 mL). The reaction mixture was transferred to a sealed tube and heated at 55 °C for 3 d. The solution was cooled and concentrated in vacuo to provide a yellow oil. This aminolysis reaction was repeated using 1.5 g of X; the products from these two reactions were combined to afford 2 g of the primary amide which was used in the next reaction without further purification.
The crude amide was dissolved in EtOH (80 mL) and ammonia was bubbled through the solution for 5 minutes. To this solution was added a catalytic amount of Raney nickel (50%) slurry in H2O). The reaction mixture was placed under
a hydrogen atmosphere (50 psi) for 3 h, filtered through celite, and concentrated in vacuo to provide 2 g of the amine which was used without further purification.
To the crude amine in dioxane (60 mL) and H2O (20 mL) at 0 °C was added NaHCO3 (2.96 g, 35.3 mmol). Fmoc-Cl (1.09 g, 4.24 mmol) was added and stirring was continued for lh. The reaction was quenched with 1 M HCl and the aqueous layer was extracted with CH2C12 (3 x). The organic layer was dried over MgSO4, concentrated in vacuo, and purified by silica gel chromatography to afford 2.2 g (77% over three steps) of 1.6 as a white solid.
1.7 Preparation of compound 1.7
To a solution of 1.6 (2.2 g, 2.8 mmol) in EtOAc (12 mL) was added HCl (4.0 M in dioxane, 12 mL). After 30 min, the reaction mixture was concentrated in vacuo and then triturated with CH2C12 (3 x) to afford 2.1 g of 1.7 as a white solid which was used without further purification.
1.8 Preparation of compound 1.8
1.8
To a portion of 1.7 (500 mg, 0.69 mmol) in CH2C12 (5 mL) was added 1.2 (383 mg, 1.38 mmol) and NMM (0.23 mL, 2.07 mmol). After stirring for 10 min, EDC (265 mg, 1.38 mmol) and HOBT (211 mg, 1.38 mmol) were added to the reaction mixture. The reaction was stirred for 10 h and then quenched with 10%
aqueous citric acid. The aqueous layer was extracted with CH2C12. The organic layer was washed with saturated NaHCO3, dried over MgSO4, and concentrated in vacuo to afford 650 mg of a colorless oil. Purification by silica gel chromatography provided 500 mg (77%) of 1.8 as a white solid.
1,9 Preparation of compound 1.9
1.9
Ester 1.8 (500 mg, 0.53 mmol) was stirred in CH2C12 (20 mL) and El^NH (5 mL) for 12 h. The reaction mixture was concentrated in vacuo and triturated with CH2C12 (3 x). The solid was redissolved in CH2C12 (3 mL) and diluted with hexanes (25 mL). The resulting precipitate was removed by filtration and the filtrate was concentrated in vacuo to yield 440 mg of 1.9 which was used without further purification.
1.10 Preparation of compound 1.10
A portion of 1.9 (50 mg, 0.07 mmol) was dissolved in CH2C12 (1 mL) and a few drops of DMF. To this solution was added 5-methanesulfonyl-2- thiophenecarboxylic acid (29 mg, 0.14 mmol), EDC (27 mg, 0.14 mmol), and NMM (50 μL, 0.54 mmol). After stirring for 12 h, the reaction mixture was concentrated in vacuo and the crude material purified by flash chromatography to yield 17 mg (27%) of 1.10 as a white solid.
1.11 Preparation of compound 1
To ester 1.10 (17 mg, 0.019 mmol) in THF / MeOH / H2O (2:2:1, 5 mL) was added LiOH (6 mg, 0.25 mmol). After 30 minutes, the reaction was quenched with 8 drops of acetic acid and the solution was concentrated in vacuo. Purification of the crude material by RP-HPLC afforded 12 mg (74%) of 1 as a white solid. ESI(-) 856.2, 857.2, 858.2, 859.2, 860.2.
EXAMPLE 2
This example illustrates the synthesis of compound 2.
2.1 Preparation of compound 2.1
To a solution of Boc-trørø-4-hydroxy-L-proline (2.5 g, 10.8 mmol) in DMF (15 mL) was added methyl 4-aminobenzoate (1.2 g, 8.3 mmol), NMM (1 mL, 10.8 mmol), HBTU (4.2 g, 11 mmol), and HOBT (1.6 g, 11 mmol). The reaction was stirred overnight and the reaction mixture was concentrated in vacuo. The residue was dissolved in EtOAc (150 mL) and the organic layer was washed with 10% aqueous citric acid and 1 N NaHCO3. The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography to afford 2.1 g (71%) of 2.1.
2.2 Preparation of compound 2.2
2.2 To a solution of alcohol 2.1 (1.8 g, 4.9 mmol) in DMF (4 mL) was added methanesulfonyl chloride (0.45 mL, 5.9 mmol) and Et3N (0.59 mL, 5.9 mmol). The solution was stirred at rt for 5 h, concentrated in vacuo, and used without further purification.
The crude mesylate was dissolved in DMF (20 mL) and sodium azide (0.9 g, 14 mmol) was added. The reaction mixture was warmed to 65 °C and stirred for 24 h. DMF was removed in vacuo and the resulting residue was dissolved EtOAc. The organic layer was washed with H2O and brine, dried over MgSO4, concentrated in vacuo, and purified by silica gel chromatography to provide 1.37 g (72%) of 2.2.
2.3 Preparation of compound 2.3
Amide 2.2 (1.3 g, 3.3 mmol) and benzyl bromide (0.47 mL, 3.7 mmol) were dissolved in DMF (10 mL) and CH2C12 (10 mL). The solution was cooled to 0 °C and NaH (60% dispersion in mineral oil, 0.15 g, 3.63 mmol) was added portionwise. The solution was slowly warmed to rt and allowed to stir for 24 h. The reaction was quenched with 10% aqueous citric acid, the solution was concentrated in vacuo, and the resulting residue was dissolved in EtOAc. The organic layer was washed with H2O and brine, dried over MgSO4, and concentrated in vacuo. Purification by silica gel chromatography provided 1.23 g (78%) of 2.3.
2.4 Preparation of compound 2.4
Ester 2.3 (1.23 g, 2.57 mmol) was stirred in HCl (4N in dioxane, 20 mL, 80 mmol) for 30 minutes. The reaction mixture was concentrated in vacuo to afford the amine HCl salt which was used in the next reaction without further purification.
The crude material was dissolved in CH2C12 (10 mL). To this solution was added Boc-L-t-butylglycine (0.80 g, 3.45 mmol), EDC (0.90 g, 4.6 mmol), HOBT (0.7 g, 4.6 mmol), and NMM (0.47 mL, 4.6 mmol). After stirring overnight, the reaction mixture was concentrated in vacuo. The residue was dissolved in EtOAc and washed with 10% aqueous citric acid, 1 N NaHCO3, and dried over MgSO4. The resulting solution was concentrated in vacuo and purified by silica gel chromatography to yield 1.0 g (66%) of 2.4 as a white solid.
2.5 Preparation of compound 2.5
Ester 2.4 (1.0 g, 1.7 mmol) was dissolved in a saturated solution of ammonia in methanol (25 mL) and stirred in a sealed tube for 42 h. The reaction was concentrated in vacuo and the residue purified by silica gel chromatography to afford 0.7 g (72%) of 2.5.
2.6 Preparation of compound 2.6
To a solution of azide 2.5 (0.2 g, 0.36 mmol) in methanol (10 mL) was added 10% Pd/C (0.036 mmol). The flask was equipped with a balloon of H2 and the reaction was stirred for 1 h. The solution was filtered through celite, concentrated in vacuo, and the material was used without further purification.
The residue was dissolved in DMF (5 mL). To this solution was added acetic anhydride (40 μL, 0.43 mmol) and NMM (0.1 mL, 1.0 mmol). After the reaction mixture was stirred for 24 h, the solvent was removed in vacuo, and the residue was dissolved in EtOAc. The organic solution was extracted with 10% aqueous citric acid and 1 N NaHCO3, dried over MgSO4, filtered, and concentrated in vacuo. Purification by silica gel chromatography provided 73 mg (36%) of 2.6.
2.7 Preparation of compound 2.7
Amide 2.6 (180 mg, 0.35 mmol) was stirred in HCl (4N in dioxane, 3 mL, 12 mmol) for 30 minutes. The reaction mixture was concentrated in vacuo to afford the HCl salt which was used in the next reaction without further purification.
The crude material was dissolved in DMF (6 mL). To this solution was added carboxylic acid 1.2 (0.1 g, 0.35 mmol), EDC (0.13 g, 0.7 mmol), HOBT (0.11 g, 0.7 mmol), and NMM (0.28 mL, 2.8 mmol). After stirring overnight, the solvent was removed in vacuo. The residue was dissolved in EtOAc and the organic layer was washed with 10% aqueous citric acid and 1 N NaHCO3. The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. Purification by silica gel chromatography provided 163 mg (62%) of 2.7.
2.8 Preparation of compound 2
To a solution of 2.7 (50 mg, 0.07 mmol) in MeOH (2 mL) was added 1 N NaOH (2 mL, 2 mmol). The reaction was stirred for 15 minutes, neutralized with concentrated HCl, and extracted with EtOAc. The organic layer was dried over MgSO4 and concentrated in vacuo. Purification by RP-HPLC provided 10 mg (22%) of 2 as a white solid. ESI(+) 698.3.
EXAMPLE 3
This example illustrates the preparation of compound 3.
3.1 Preparation of compound 3.1
3.1
To a suspension of 4-iodobenzoyl chloride (9.86 g, 37 mmol) in triethylphosphite (8.2 mL, 47.9 mmol) was added toluene (50 mL). The reaction mixture was heated to reflux for 30 minutes, cooled to rt, and then concentrated in vacuo.
The residue was cooled to 0 °C and diethylaminosulfur trifluoride (20 mL, 152 mmol) was added portionwise. The reaction was stirred at 0 °C for 3 h, diluted with CH2C12, and then quenched with saturated aqueous NaHCO3 at 0 °C. The aqueous layer was washed with CH2C12, EtOAc, and hexanes. The combined organic portions were dried over MgSO4, concentrated in vacuo and purified by silica gel chromatography to provide 2.3 g (16%) of 3.1.
3.2 Preparation of compound 3.2
To a solution of the iodide 3.1 (1.37 g, 3.5 mmol) in Et3N (15 mL) was added t-butyl acrylate (1.02 mL, 6.9 mmol), Pd(OAc)2 (79 mg, 0.35 mmol, and tri-o- tolylphosphine (106 mg, 0.35 mmol). The reaction mixture was heated to 60 °C for 2 h at which time starting material still remained. Additional t-butyl acrylate (1.02 mL, 6.9 mmol) and Pd(OAc)2 (35 mg, 0.17 mmol) were added and the reaction mixture was stirred for 3 h. The solution was cooled to rt, filtered through celite, and concentrated in vacuo. Silica gel chromatography provided 1.15 g (84%) of 3.2 as an orange oil.
3.3 Preparation of compound 3.3
3.3
Ester 3.2 (1.5 g, 3.84 mmol) was dissolved in CH2C12 / TFA (1:1, 20 mL). After 1 h, the solution was concentrated in vacuo and the residue was used without further purification.
3.4 Preparation of compound 3.4
To the acid 3.3 (178 mg, 0.53 mmol) in CH2C12 (5 mL) was added bis(trimethylsilyl)trifluoroacetamide (0.14 mL, 0.53 mmol). After 30 minutes, the reaction was cooled to 0 °C and iodotrimethylsilane (0.30 mL, 2.1 mmol) was added. The reaction was stirred at 0 °C for 30 min and then at rt for 30 min. The solution was concentrated in vacuo. The residue was dissolved in CH3CN / H2O / TFA (10:5:3, 9 mL), stirred an additional 30 minutes, concentrated in vacuo, and used without further purification.
3.5 Preparation of compound 3.5
To a solution of Boc-L-proline (2.3 g, 10.7 mmol) in CH2C12 (50 mL) was added 4-iodoaniline (2.3 g, 10.5 mmol) and EDC (2.1 g, 11.0 mmol). After 4 h, the reaction was quenched with 1 N HCl. The organic layer was washed with 1 N NaOH, dried over MgSO4, and concentrated in vacuo to provide 4.4 g of a foam which was used without further purification.
The foam was dissolved in CH2C12 and to this solution was added triphenylbismuth (7.0 g, 15.9 mmol), Cu(OAc)2 (2.9 g, 15.9 mmol) and Et3N (3 mL, 21.6 mmol). The reaction was stirred vigorously overnight, filtered through celite,
and the filtrate was concentrated in vacuo. Partial purification by flash chromatography afforded 4.4 g of a diphenylamide foam which was used in the next reaction without additional purification.
The diphenyl amide was dissolved in CH2C12 / TFA (1 : 1, 40 mL) and stirred 30 minutes. The solvents were removed in vacuo to provide 3.1 g of the TFA salt which was used in the next reaction without further purification.
The amine TFA salt was dissolved in CH2C12 (20 mL) and to this solution was added Boc-L-t-butylglycine (2.2 g, 9.5 mmol), EDC (1.8 g, 9.5 mmol), and Et3N (1.3 mL, 17.7 mmol). After 6 h, the reaction was quenched with 1 N HCl; the organic layer was washed with 1 N NaOH and brine, dried over MgSO4, and concentrated in vacuo. The material was purified by silica gel chromatography.
The Boc group was removed by dissolving the material in CH2C12 / TFA (1:1, 10 mL). After 30 minutes, the solvents were removed in vacuo. The residue was dissolved in CH2C12; the organic layer was extracted with 1 N NaOH, dried over MgSO4, and concentrated in vacuo to provide 0.53 g (8% over 5 steps) of 3.5.
3.6 Preparation of compound 3.6
3.6
Phosphonate 3.4 (29 mg, 0.1 mmol) and amine-TFA salt 3.5 (35 mg, 0.07 mmol) were dissolved in DMF (2 mL). To this solution was added HOBT (15 mg, 0.1 mmol), N,N-diisopropylethylamine (49 μL, 0.28 mmol), and HBTU (38 mg, 0.1 mmol). After stirring overnight, the reaction was quenched with 0.5 M HCl (10 mL) resulting in precipitate formation. The mixture was placed in a refrigerator for 2 h and then filtered to provide 28 mg of a tan solid. Purification by RP-HPLC afforded 5.8 mg (11%) of 3.6 as a white solid. ESI(-) 765.5.
3.7 Preparation of compound 3
To a suspension of phosphonate 3.6 (150 mg, 0.2 mmol) in H2O was added NaOH (18 mg, 0.45 mmol). To this slightly cloudy solution was added AgNO3 (68 mg, 0.42 mmol). The round-bottom flask was wrapped in foil and transferred to a refrigerator. After 3 h, the solution was filtered, the solid was suspended in dry toluene (3 mL), and iodomethyl pivalate (145 mg, 0.6 mmol) was added. After stirring overnight, solvent was removed in vacuo and the residue was purified by silica gel chromatography to afford 3 as an off-white foam. ESI(+) 994.2.
EXAMPLE 4
Using methods similar to those described in Examples 1 and 2, the compounds provided in Table 1 were prepared and evaluated as inhibitors of STAT6 binding (duplex formation). The assay is described in co-pending application Ser. No. 09/053,003, filed March 31, 1998. In each of the tables below: a + symbol indicates an IC50 of >100 μM; a ++ symbol indicates an IC50 of <100 μM.
TABLE 1
EXAMPLE 5
Compounds having the formulae provided in Table 2 were prepared using methodology similar to that provided in the Examples above.
TABLE 2
The compounds shown in Tables 3, 4 and 5 were prepared using steps similar to those described in the examples above. In many instances the starting materials were different and certain additional steps involving reductions and/or acylations were used.
TABLE 3
TABLE 5
EXAMPLE 7
Compounds having the formulae provided in Table 6 were prepared using methodology similar to that provided in the Examples above. All compounds exhibited an IC50 below 100 micromolar in a fluorescence polarization assay.
TABLE 6
All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain
changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Claims
1. A compound having the formula:
R1 and R2 are each members independently selected from the group consisting of hydrogen, ( -C^alkyl, (CrC8)heteroalkyl, aryl, heteroaryl, aryl(Cr C8)alkyl, aryl(C1-C8)heteroalkyl, heteroaryl(CrCs)alkyl, and heteroaryl(C1-C8)heteroalkyl,with the proviso that at least one of R1 and R2 is selected from the group consisting of aryl, heteroaryl, aryl(C,-C8)alkyl, aryl(C1-C8)heteroalkyl, heteroaryl(CrC8)alkyl and heteroaryl(C,-C8)heteroalkyl;
A1 is a member selected from the group consisting of L-α-amino acid fragments, D-α-amino acid fragments and fragments having the formula:
R3 is selected from the group consisting of hydrogen and (CrC4) alkyl;
R4 and R5 are each members independently selected from the group consisting of hydrogen, (CrC8)alkyl and (CrC8)heteroalkyl, or can be individually combined with R3 to form a 5-, 6-, 7- or 8- membered ring containing from one to three heteroatoms; A2 is a member selected from the group consisting of L-α-amino acid fragments, D-α-amino acid fragments and fragments having the formula: wherein
R6 is selected from the group consisting of hydrogen and (CrC4)alkyl; R7 and R8 are each members independently selected from the group consisting of hydrogen, (CrC8)alkyl and or can be combined with each other to form a 5-, 6-, 7- or 8- membered ring containing from zero to three heteroatoms; X is a member selected from the group consisting of a bond, a (Cj-C4) saturated or unsaturated alkylene linking group and a (CrC4) saturated or unsaturated heteroalkylene linking group; Ar is an aryl or heteroaryl group; and Y is a member selected from the group consisting of:
-B^Z1 and -B2-(ZJ)(Z2) wherein B1 is a bond or a divalent linking group; B2 is a trivalent linking group; Z1 is a member selected from the group consisting of -CO2R9,
-P(O)(OR9)(OR10), -P(O)(R9)(OR10), -S(O)2(OR9), -S(O)(OR9) and a carboxylic acid isostere; and Z2 is a member selected from the group consisting of -CO2R9, -NHR11, -P(O)(OR9)(OR10), -P(O)(R9)(OR10), -S(O)2(OR9), -S(O)(OR9) and a carboxylic acid isostere; wherein
R9 and R10 are each independently selected from the group consisting of H, (CrC8)alkyl, aryl and (Cj-C^heteroalkyl; and Ru is (CrC8)alkyl.
2. A compound of claim 1, wherein R1 and R2 are each members independently selected from the group consisting of (C1-C8)alkyl, aryl and aryl(Cι- C8)alkyl.
3. A compound of claim 1, wherein R1 is an optionally substituted phenyl group.
4. A compound of claim 1, wherein R1 is an optionally substituted phenyl group and R2 is an optionally substituted benzyl group.
6. A compound of claim 1, wherein R1 and R2 are each independently optionally substituted benzyl groups.
7. A compound of claim 1, wherein R1 is an optionally substituted phenyl group and R2 is a (CrC4)alkyl or (CrC4)heteroalkyl group.
8. A compound of claim 1, wherein R1 is a substituted phenyl group selected from 4-tolyl, 4-chlorophenyl, 4-iodophenyl, 4-bromophenyl, 4-methoxyphenyl, 4- hydroxyphenyl, 4-carbamoylphenyl, 4-carboxyphenyl and 4-carbomethoxyphenyl.
9. A compound of claim 1, wherein R1 is a phenyl group substituted with up to two members selected from the group consisting of-NHCONH2, -C(NH)NH2, -CONH2, -CH2NHCO-(4-nitro-2-pyrazolyl), -CONHPh, -CH2NH2, -CH2NHCO-CH=CH-(3-nitrophenyl), -CH3, -Cl, -Br, -I, -CO2H, -CO2CH3, -OCH3, -OH, -Ph, -OPh, -CON(CH3)2, -C(CH3)3, -CH2NHAc, -CN and -CH2NHCO-CH=CH-(4-pyridyl).
10. A compound of claim 1, wherein A1 is selected from L-tyrosine, L-serine, L-methionine, L-alanine and L-proline .
11. A compound of claim 1, wherein A1 is a fragment having the formula:
12. A compound of claim 11, wherein A1 is selected from the group consisting of
13. A compound of claim 11, wherein R3 and R4 are combined to form a 5-membered ring.
14. A compound of claim 1, wherein A1 is represented by the formula:
15. A compound of claim 1, wherein A2 is selected from L- valine, L-leucine, L-lysine, L-methionine, L-threonine, L-isoleucine and L-tert-butylglycine.
16. A compound of claim 1, wherein A2 is selected from L- valine, L-leucine, L-lysine, L-methionine, L-threonine, L-isoleucine and L-tert-butylglycine, and R1 and R2 are each members independently selected from the group consisting of aryl and aryl(C1-C8)alkyl.
17. A compound of clai 1, wherein A2 is a fragment having the formula:
18. A compound of claim 16, wherein A2 is L-valine or L-tert-butylglycine.
19. A compound of claim 1, wherein X is selected from -OCH2-, -CH2CH2-, -CH=CH- and -CH=C(CH3)-.
20. A compound of claim 1, wherein Ar represents an optionally substituted benzene ring.
21. A compound of claim 1, wherein Y is -B^Z1.
22. A compound of claim 21, wherein B1 is selected from a bond, -O-, -CH2-, -CHF-, -CH(OH)-, -CF2-, -OCH2-, -CH2CH2-, -CF2CF2-, -OCF2-, -OCHF- and -CHF-CHF-, and Z1 is selected from -CO2R9, -P(O)(OR9)(OR10), -P(O)(R9)(OR10) and a carboxylic acid isostere.
23. A compound of claim 1, wherein Y is -B2-(Z1)(Z2).
24. A compound of claim 23, wherein B2 is selected from of -O-CF<, -CH<, -O-CH<, -C(OH)<, -CH2-CH< and -CH=C<, and Z1 and Z2 are each independently selected from -CO2R9, -P(O)(OR9)(OR10), -P(O)(R9)(OR10) and a carboxylic acid isostere.
25. A compound of claim 1, wherein R9 and R10 are each independently selected from hydrogen and (C1-C8)alkyl.
26. A compound of claim 1, wherein A1 is an amino acid fragment wherein the amino acid is selected from L-proline and L-alanine, A2 is a second amino acid fragment wherein the second amino acid is selected from L-valine, L-leucine, L- isoleucine, L-tert-butylglycine, and R1 and R2 are each members independently selected from the group consisting of (Cj-C8)alkyl, aryl, heteroaryl, aryl(C1-C8)alkyl and heteroaryl(C1-C8)alkyl.
27. A compound of claim 1, wherein A1 is an amino acid fragment wherein the amino acid is selected from L-proline and L-alanine, A2 is a second amino acid fragment wherein the second amino acid is selected from L-valine, L-leucine, L- isoleucine, L-tert-butylglycine, R1 is (C,-C8)alkyl, and R2 is selected from the group consisting of aryl and aryl(C,-C8)alkyl.
28. A compound of claim 1, wherein A1 is a fragment derived from L-proline, A2 is a fragment derived from L-tert-butylglycine, and R1 and R2 are each members independently selected from the group consisting of (C,-C8)alkyl, aryl, heteroaryl, aryl(Cι-C8)alkyl and heteroary^Cj-C^alkyl.
29. A compound of claim 1, wherein A1 is a fragment derived from L-proline, A2 is a fragment derived from L-tert-butylglycine, R1 is (C1-C8)alkyl, and R2 is selected from the group consisting of aryl and aryl(C1-C8)alkyl.
30. A compound of claim 1, wherein A1 is a fragment derived from L-proline, A2 is a fragment derived from L-tert-butylglycine, X is selected from the group consisting of -CH=CH- and -C(CH3)=CH-, Ar is benzene, R1 and R2 are each members independently selected from the group consisting of aryl, heteroaryl, aryl(C,-C8)alkyl and heteroaryl(C1-C8)alkyl.
31. A compound of claim 1, wherein A1 is a fragment derived from L-proline, A2 is a fragment derived from L-tert-butylglycine, X is selected from the group consisting of -CH=CH- and -C(CH3)=CH-, Ar is benzene, R1 is (CrC8)alkyl, and R2 is selected from the group consisting of aryl and aryl(C,-C8)alkyl.
32. A compound of claim 1, having the formula:
W1 represents a member selected from the group consisting of -H, -OR12 and
-NR12R13 ; W2, W3 and W4 each independently represent a member selected from the group consisting of halogen, -R14, -CO2R14, -OR14, -NR14R15 and
-CONR14R15; wherein each of R12, R13, R14 and R15 independently represent a member selected from the group consisting of hydrogen, aryl, (C1-C3)alkyl, (Cr
33. A compound of claim 1, having the formula:
W1 represents a member selected from the group consisting of -H, -OR12 and
-NR12R13 ; W2, W3 and W4 each independently represent a member selected from the group consisting of halogen, -R14, -CO2R14, -OR14, -NR14R15 and
-CONR14R15; wherein each of R12, R13, R14 and R15 independently represent a member selected from the group consisting of hydrogen, aryl, (CrC8)alkyl, (C,-
34. A compound of claim 1, having the formula:
W1 represents a member selected from the group consisting of -H, -OR12 and
-NR12R13 ; W2, W3 and W4 each independently represent a member selected from the group consisting of halogen, -R14, -CO2R14, -OR14, -NR14R15 and
-CONR14R15; wherein each of R12, R13, R14 and R15 independently represent a member selected from the group consisting of hydrogen, aryl, (C,-C8)alkyl, (C
C8)heteroalkyl, aryl(C1-C8)alkyl, aryl(CrC8)heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl; and W5 is a member selected from the group consisting of H and (Cj-C3)alkyl.
35. A composition comprising a pharmaceutically acceptable excipient and a compound having the formula:
R1 and R2 are each members independently selected from the group consisting of hydrogen, (CrC8)alkyl, (CrC8)heteroalkyl, aryl, heteroaryl, ary^C,- C8)alkyl, aryl(CrC8)heteroalkyl, and heteroaryl(C,-C8)heteroalkyl,with the proviso that at least one of R1 and R2 is selected from the group consisting of aryl, heteroaryl, aryl(C1-C8)alkyl, ary^ -C^heteroalkyl, heteroaryl(CrC8)alkyl and heteroaryl(C -C8)heteroalky 1;
A1 is a member selected from the group consisting of L-α-amino acid fragments, D-α-amino acid fragments and fragments having the formula:
R3 is selected from the group consisting of hydrogen and ( - ) alkyl; R4 and R5 are each members independently selected from the group consisting of hydrogen, or can be individually combined with R3 to form a 5-, 6-, 7- or 8- membered ring containing from one to three heteroatoms; A2 is a member selected from the group consisting of L-α-amino acid fragments, D-α-amino acid fragments and fragments having the formula:
X R!6 Ύ O wherein
R6 is selected from the group consisting of hydrogen and (CrC4)alkyl; R7 and R8 are each members independently selected from the group consisting of hydrogen, (CrC8)alkyl and (CrC8)heteroalkyl, or can be combined with each other to form a 5-, 6-, 7- or 8- membered ring containing from zero to three heteroatoms; X is a member selected from the group consisting of a bond, a (C C4) saturated or unsaturated alkyl linking group and a (C]-C4) saturated or unsaturated heteroalkyl linking group; Ar is an aryl or heteroaryl group; and Y is a member selected from the group consisting of:
-B^Z -B Z'XZ2) wherein B1 is a bond or a divalent linking group; B2 is a trivalent linking group; Z1 is a member selected from the group consisting of -CO2R9,
-P(O)(OR9)(OR10), -P(O)(R9)(OR10), -S(O)2(OR9), -S(O)(OR9) and a carboxylic acid isostere; and Z2 is a member selected from the group consisting of -CO2R9, -NHR11,
-P(O)(OR9)(OR10), -P(O)(R9)(OR10), -S(O)2(OR9), -S(O)(OR9) and a carboxylic acid isostere; wherein
36. A composition in accordance with claim 35, wherein R1 and R2 are each members independently selected from the group consisting of (C,-C8)alkyl, aryl and aryl(CrC8)alkyl.
37. A composition in accordance with claim 35, wherein R1 is an optionally substituted phenyl group.
38. A composition in accordance with claim 35, wherein R1 is an optionally substituted phenyl group and R2 is an optionally substituted benzyl group.
39. A composition in accordance with claim 35, wherein R1 is an optionally substituted (C,-C8)alkyl or (C1-C8)heteroalkyl group and R2 is an optionally substituted phenyl or benzyl group.
40. A composition in accordance with claim 35, wherein wherein R1 and R2 are each independently optionally substituted benzyl groups.
41. A composition in accordance with claim 35, wherein R1 is a substituted phenyl group selected from 4-tolyl, 4-chlorophenyl, 4-iodophenyl, 4-methoxyphenyl, 4-hydroxyphenyl, 4-carbamoylphenyl, 4-carboxyphenyl and 4-carbomethoxyphenyl.
42. A composition in accordance with claim 35 wherein R1 is a phenyl group substituted with up to two members selected from the group consisting of -C(NH)NH2, -NHCONH2, -CONH2, -CH2NHCO-(4-nitro-2-pyrazolyl), -CONHPh, -CH2NH2, -CH2NHCO-CH=CH-(3-nitrophenyl), -CH3, -Cl, -I, -CO2H, -CO2CH3, -OCH3, -OH, -Ph, -OPh, -CON(CH3)2, -C(CH3)3, -CH2NHAc, -CN and -CH2NHCO-CH=CH-(4-pyridyl).
43. A composition in accordance with claim 35, wherein A1 is an amino acid fragment, wherein the amino acid is a member selected from L-tyrosine, L-serine, L- methionine, L-alanine and L-proline .
44. A composition in accordance with claim 35, wherein A1 is a fragment having the formula:
45. A composition in accordance with claim 44, wherein A1 is a fragment selected from the group consisting of
46. A composition in accordance with claim 44, wherein R3 and R4 are combined to form a 5-membered ring.
47. A composition in accordance with claim 35, wherein A1 is represented by the formula:
48. A composition in accordance with claim 35, wherein A2 is an amino acid fragment, wherein the amino acid is a member selected from L-valine, L-leucine, L- lysine, L-methionine, L-threonine, L-isoleucine and L-tert-butylglycine.
49. A composition in accordance with claim 35, wherein A2 is an amino acid fragment, wherein the amino acid is a member selected from L-valine, L-leucine, L- lysine, L-methionine, L-threonine, L-isoleucine and L-tert-butylglycine, and R1 and R2 are each members independently selected from the group consisting of aryl and aryl(CrC8)alkyl.
50. A composition in accordance with claim 35, wherein A2 is a fragment having the formula:
51. A composition in accordance with claim 49, wherein A2 is an amino acid fragment, wherein the amino acid is L-valine or L-tert-butylglycine.
52. A composition in accordance with claim 35, wherein X is selected from - OCH2-, -CH2CH2-, -CH=CH-, and -CH=C(CH3)-.
53. A composition in accordance with claim 35, wherein Ar represents an optionally substituted benzene ring.
55. A composition in accordance with claim 54, wherein B1 is selected from a bond, -O-, -CH2-, -CHF-, -CH(OH)-, -CF2-, -OCH2-, -CH2CH2-, -CF2CF2-, -OCF2-, -OCHF- and -CHF-CHF-, and Z1 is selected from -CO2R9, -P(O)(OR9)(OR10), -P(O)(R9)(OR10) and a carboxylic acid isostere.
56. A composition in accordance with claim 35, wherein Y is -B2-(Z1)(Z2).
57. A composition in accordance with claim 56, wherein B2 is selected from of -O-CF<, -CH<, -C(OH)<, -O-CH<, -CH2-CH< and -CH=C<, and Z1 and Z2 are each independently selected from -CO2R9, -P(O)(OR9)(OR10), -P(O)(R9)(OR10) and a carboxylic acid isostere.
58. A composition in accordance with claim 35, wherein R9 and R10 are each independently selected from hydrogen and (C,-C8)alkyl.
59. A composition in accordance with claim 35, wherein A1 is an amino acid fragment, wherein the amino acid is a member selected from L-proline and L-alanine, A2 is a second amino acid fragment, wherein the second amino acid is a member selected from L-valine, L-leucine, L-isoleucine, and L-tert-butylglycine, and R1 and R2 are each members independently selected from the group consisting of ( - C8)alkyl, aryl and ary^ -C^alkyl.
60. A composition in accordance with claim 35, wherein A1 is an amino acid fragment, wherein the amino acid is a member selected from L-proline and L-alanine, A2 is a second amino acid fragment, wherein the second amino acid is a member selected from L-valine, L-leucine, L-isoleucine, and L-tert-butylglycine; R1 is ( -C^alkyl, and R2 is selected from the group consisting of (C1-C8)alkyl, aryl and aryl(CrC8)alkyl.
63. A composition in accordance with claim 35, wherein A1 is a L-proline fragment, A2 is a L-tert-butylglycine fragment, X is selected from the group consisting of -CH=CH- and -C(CH3)=CH-, Ar is benzene, R1 and R2 are each members independently selected from the group consisting of aryl and aryl(Cj-C8)alkyl.
64. A composition in accordance with claim 35, wherein A1 is a L-proline fragment, A2 is a L-tert-butylglycine fragment, X is selected from the group consisting of -CH-CH- and -C(CH3)=CH-, Ar is benzene, R1 is (CrC8)alkyl, and R2 is selected from the group consisting of aryl and aryl(CrC8)alkyl.
65. A composition in accordance with claim 35, said compound having the formula:
W1 represents a member selected from the group consisting of -H, -OR12 and
-NR12R13 ; W2, W3 and W4 each independently represent a member selected from the group consisting of halogen, -R14, -CO2R14, -OR14, -NR14R15 and -CONR14R15; wherein each of R12, R13, R14 and R15 independently represent a member selected from the group consisting of hydrogen, aryl, (CrCg)alkyl, (C Cg)heteroalkyl, aryl(CrC8)alkyl, aryl(CrC8)heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl; and
W5 is a member selected from the group consisting of H and (C1-C8)alkyl.
66. A composition of claim 35, said compound having the formula:
W1 represents a member selected from the group consisting of -H, -OR12 and
-NR12R13 ; W2, W3 and W4 each independently represent a member selected from the group consisting of halogen, -R14, -CO2R14, -OR14, -NR14R15 and
-CONR14R15; wherein each of R12, R13, R14 and R15 independently represent a member selected from the group consisting of hydrogen, aryl, (CrCg)alkyl, (C
Cg)heteroalkyl, ary^ -C^alkyl, ary^ -C^heteroalkyl, alkylsulfonyl, arylsulfonyl and arylsulfinyl; and W5 is a member selected from the group consisting of H and (CrC8)alkyl; and W6 is a member selected from the group consisting of (CrC8)alkyl.
67. A composition of claim 35, said compound having the formula:
W1 represents a member selected from the group consisting of-H, -OR12 and
-NR1 R13 ; W2, W3 and W4 each independently represent a member selected from the group consisting of halogen, -R14, -CO2R14, -OR14, -NR14R15 and
-CONR1 R15; wherein each of R12, R13, R14 and R15 independently represent a member selected from the group consisting of hydrogen, aryl, (Cj-C8)alkyl, (C,-
68. A method for modulating a STAT6-dependent condition in a host, comprising administering to said host a STAT6-modulating amount of a compound according to claim 1.
69. A method for modulating a STAT6-dependent condition in a host, comprising administering to said host a STAT6-modulating amount of a composition according to claim 35.
70. A method in accordance with claim 68, wherein said STAT6-dependent condition is selected from the group consisting of allergic rhinitis, asthma, atopic dermatitis, contact dermatitis, anaphylaxis, food or drug induced allergy, conjunctivitis, uveitis, hypersensitivity reactions, alveolitis, psoriasis, Churg-Strauss syndrome, delayed-type hypersensitivity, urticaria, angiodema, eczema, scleroderma, and systemic lupus erythematosus.
71. A method for treating a condition in a host, comprising administering to said host an effective amount of a compound of claim 1, wherein said condition is selected from the group consisting of allergic rhinitis, asthma, atopic dermatitis, contact dermatitis, anaphylaxis, food or drug induced allergy, conjunctivitis, uveitis, hypersensitivity reactions, alveolitis, psoriasis, Churg-Strauss syndrome, delayed-type hypersensitivity, urticaria, angiodema, eczema, scleroderma, and systemic lupus erythematosus.
72. A method in accordance with claim 71, wherein said compound of claim 1 is administered in combination with a second therapeutic agent.
73. A method in accordance with claim 72, wherein said second therapeutic agent is selected from the group consisting of loratidine, fluticasone propionate, beclametasone diproprionate, budesonide, salmeterol xinafoate, ipratropium bromide, fexofenadine hydrochloride, cetirizine dihydrochloride, triamcinolone acetonide, cromolyn, salbutamol, montelukast sodium, ketotifen hydrogen fumarate, formoterol, zafirlukast, momefasone furoate, azelastine hydrochloride, epinastine, seratrodast, captropril, rampril, zofenopril, colchicine, enalapril, lisinopril, trandolapril, gold sodium thiomalate, calcipotriene, cyclosporine, vinblastine and dapsone.
74. A method in accordance with claim 73, wherein said compound of claim 1 and said second therapeutic agent are administered sequentially.
75. A method in accordance with claim 73, wherein said compound of claim 1 and said second therapeutic agent are administered concurrently.
76. A method in accordance with claim 73, wherein said compound of claim 1 and said second therapeutic agent are each administered at dosages of from 1/100 to 1/2 of their dosages when administered individually.
77. A method in accordance with claim 73, wherein said compound of claim 1 and said second therapeutic agent are each administered at dosages of from 1/10 to 1/4 of their dosages when administered individually.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2000249828A AU2000249828A1 (en) | 2000-05-03 | 2000-05-03 | Stat4 and stat6 binding dipeptide derivatives |
PCT/US2000/012079 WO2001083517A1 (en) | 2000-05-03 | 2000-05-03 | Stat4 and stat6 binding dipeptide derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2000/012079 WO2001083517A1 (en) | 2000-05-03 | 2000-05-03 | Stat4 and stat6 binding dipeptide derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001083517A1 true WO2001083517A1 (en) | 2001-11-08 |
Family
ID=21741350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/012079 WO2001083517A1 (en) | 2000-05-03 | 2000-05-03 | Stat4 and stat6 binding dipeptide derivatives |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2000249828A1 (en) |
WO (1) | WO2001083517A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002038107A2 (en) * | 2000-11-08 | 2002-05-16 | Tularik Inc. | Stat modulators |
WO2005060956A1 (en) * | 2003-12-12 | 2005-07-07 | University Of Maryland, Baltimore | IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN |
US7622496B2 (en) | 2005-12-23 | 2009-11-24 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
US7659268B2 (en) | 2005-11-08 | 2010-02-09 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
US7829528B2 (en) | 2004-09-14 | 2010-11-09 | The Rockefeller University | Compositions and methods for treating STAT-6 associated diseases or conditions |
US8039491B2 (en) | 2005-12-28 | 2011-10-18 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US8124781B2 (en) | 2007-12-07 | 2012-02-28 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
US8841257B2 (en) | 2009-04-10 | 2014-09-23 | Board Of Regents, The University Of Texas System | Inhibitors of STAT3 and uses thereof |
WO2014182928A2 (en) * | 2013-05-08 | 2014-11-13 | Board Of Regents, The University Of Texas System | Stat6 inhibitors |
US8927590B2 (en) | 2006-12-21 | 2015-01-06 | Zealand Pharma A/S | Synthesis of pyrrolidine compounds |
US9725440B2 (en) | 2007-05-09 | 2017-08-08 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
US9751890B2 (en) | 2008-02-28 | 2017-09-05 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as CFTR modulators |
US9840499B2 (en) | 2007-12-07 | 2017-12-12 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
US10076513B2 (en) | 2010-04-07 | 2018-09-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
US10231932B2 (en) | 2013-11-12 | 2019-03-19 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
US10302602B2 (en) | 2014-11-18 | 2019-05-28 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
US11324799B2 (en) | 2017-05-05 | 2022-05-10 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
EP4302768A2 (en) | 2017-06-22 | 2024-01-10 | Board Of Regents, The University Of Texas System | Methods for producing regulatory immune cells and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997005162A1 (en) * | 1995-07-28 | 1997-02-13 | Basf Aktiengesellschaft | Process for producing dolastatin 15 and intermediates thereof |
WO1998031704A2 (en) * | 1997-01-14 | 1998-07-23 | Novartis Ag | Tachykinin antagonists |
WO1999050283A1 (en) * | 1998-03-31 | 1999-10-07 | Tularik Inc. | High throughput screening assays for modulators of stat4 and stat6 activity |
-
2000
- 2000-05-03 WO PCT/US2000/012079 patent/WO2001083517A1/en active Application Filing
- 2000-05-03 AU AU2000249828A patent/AU2000249828A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997005162A1 (en) * | 1995-07-28 | 1997-02-13 | Basf Aktiengesellschaft | Process for producing dolastatin 15 and intermediates thereof |
WO1998031704A2 (en) * | 1997-01-14 | 1998-07-23 | Novartis Ag | Tachykinin antagonists |
WO1999050283A1 (en) * | 1998-03-31 | 1999-10-07 | Tularik Inc. | High throughput screening assays for modulators of stat4 and stat6 activity |
Non-Patent Citations (2)
Title |
---|
BLOMMERS, MARCEL J. J. ET AL: "Transferred cross-correlated relaxation complements transferred NOE: Structure of an IL-4R-derived peptide bound to STAT-6", J. AM. CHEM. SOC. (1999), 121(9), 1949-1953, XP002158666 * |
YAO BETTY BEI ET AL: "Direct interaction of STAT4 with the IL-12 receptor.", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 368, no. 1, 1 August 1999 (1999-08-01), pages 147 - 155, XP000972870, ISSN: 0003-9861 * |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002038107A3 (en) * | 2000-11-08 | 2002-07-25 | Tularik Inc | Stat modulators |
US6884782B2 (en) | 2000-11-08 | 2005-04-26 | Amgen Inc. | STAT modulators |
WO2002038107A2 (en) * | 2000-11-08 | 2002-05-16 | Tularik Inc. | Stat modulators |
WO2005060956A1 (en) * | 2003-12-12 | 2005-07-07 | University Of Maryland, Baltimore | IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN |
US10626111B2 (en) | 2004-01-30 | 2020-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7829528B2 (en) | 2004-09-14 | 2010-11-09 | The Rockefeller University | Compositions and methods for treating STAT-6 associated diseases or conditions |
US9216969B2 (en) | 2005-11-08 | 2015-12-22 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US11084804B2 (en) | 2005-11-08 | 2021-08-10 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7741321B2 (en) | 2005-11-08 | 2010-06-22 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7956052B2 (en) | 2005-11-08 | 2011-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7973038B2 (en) | 2005-11-08 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7659268B2 (en) | 2005-11-08 | 2010-02-09 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7622496B2 (en) | 2005-12-23 | 2009-11-24 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
US8431540B2 (en) | 2005-12-23 | 2013-04-30 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
US8039491B2 (en) | 2005-12-28 | 2011-10-18 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US8927590B2 (en) | 2006-12-21 | 2015-01-06 | Zealand Pharma A/S | Synthesis of pyrrolidine compounds |
US9469609B2 (en) | 2006-12-21 | 2016-10-18 | Zealand Pharma A/S | Synthesis of pyrrolidine compounds |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
US9725440B2 (en) | 2007-05-09 | 2017-08-08 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
US12065432B2 (en) | 2007-12-07 | 2024-08-20 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
US8124781B2 (en) | 2007-12-07 | 2012-02-28 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
US9840499B2 (en) | 2007-12-07 | 2017-12-12 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
US10597384B2 (en) | 2007-12-07 | 2020-03-24 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
US9776968B2 (en) | 2007-12-07 | 2017-10-03 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
US9751890B2 (en) | 2008-02-28 | 2017-09-05 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as CFTR modulators |
US8841257B2 (en) | 2009-04-10 | 2014-09-23 | Board Of Regents, The University Of Texas System | Inhibitors of STAT3 and uses thereof |
US10076513B2 (en) | 2010-04-07 | 2018-09-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
US11052075B2 (en) | 2010-04-07 | 2021-07-06 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
AU2014262621B2 (en) * | 2013-05-08 | 2018-03-01 | Baylor College Of Medicine | STAT6 inhibitors |
US10385080B2 (en) | 2013-05-08 | 2019-08-20 | Board Of Regents, The University Of Texas System | STAT6 inhibitors |
US9765099B2 (en) | 2013-05-08 | 2017-09-19 | Board Of Regents, The University Of Texas System | STAT6 inhibitors |
JP2016526023A (en) * | 2013-05-08 | 2016-09-01 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | STAT6 inhibitor |
WO2014182928A3 (en) * | 2013-05-08 | 2015-01-22 | Board Of Regents, The University Of Texas System | Stat6 inhibitors |
WO2014182928A2 (en) * | 2013-05-08 | 2014-11-13 | Board Of Regents, The University Of Texas System | Stat6 inhibitors |
US10231932B2 (en) | 2013-11-12 | 2019-03-19 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
US10302602B2 (en) | 2014-11-18 | 2019-05-28 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
US11324799B2 (en) | 2017-05-05 | 2022-05-10 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
EP4302768A2 (en) | 2017-06-22 | 2024-01-10 | Board Of Regents, The University Of Texas System | Methods for producing regulatory immune cells and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2000249828A1 (en) | 2001-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6426331B1 (en) | Inhibitors of STAT function | |
US6884782B2 (en) | STAT modulators | |
WO2001083517A1 (en) | Stat4 and stat6 binding dipeptide derivatives | |
US9579307B2 (en) | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators | |
US11999695B2 (en) | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | |
JP4086316B2 (en) | Novel N- (arylsulfonyl) amino acid derivative having affinity for bradykinin receptor | |
EP0696593A2 (en) | Inhibitors of farnesyl protein transferase | |
JPH06505963A (en) | Retroviral protease inhibitors | |
SK56798A3 (en) | Protease inhibitors, pharmaceutical composition containing them and their use | |
BG64470B1 (en) | Cellular adhesion inhibitors, method for their conversion, usage, pharmaceutical composition and preparation thereof | |
SK94196A3 (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them, manufacturing process thereof and their use | |
US8859605B2 (en) | Cysteine protease inhibitors | |
AU2001286542A1 (en) | Integrin receptor inhibitors | |
US6949534B2 (en) | Cell adhesion inhibitors | |
JPH05509331A (en) | N-(mercaptoalkyl)amide | |
WO1997009066A1 (en) | Fas LIGAND SOLUBILIZATION INHIBITOR | |
US6277876B1 (en) | Matrix metalloproteinase inhibitors | |
AU776171B2 (en) | Alpha-amino-beta-sulfonyl hydroxamic acid compounds | |
MXPA05012884A (en) | Benzamide nitrile derivatives. | |
JP2000514787A (en) | Thiadiazole amide MMP inhibitor | |
EP2582660B1 (en) | New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions | |
WO2011069149A2 (en) | Cathepsin s inhibitors | |
WO2001027138A2 (en) | Modulators of srebp processing | |
WO1999012912A1 (en) | Thiourea derivatives or non-toxic salts thereof for inhibitng ras-transformed cell growth | |
WO2021262708A1 (en) | Prodrugs of mitochodria-targeting oligopeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |